[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 485
11. Selva DM, Hogeveen KN, Innis SM, Hammond GL: Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest; 2007 Dec;117(12):3979-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In overweight children and adults, low plasma SHBG levels are a biomarker of the metabolic syndrome and its associated pathologies.
  • Here, we showed in transgenic mice and HepG2 hepatoblastoma cells that monosaccharides (glucose and fructose) reduce human SHBG production by hepatocytes.
  • The dose-dependent reduction of HNF-4alpha levels in HepG2 cells after treatment with glucose or fructose occurred in concert with parallel increases in cellular palmitate levels and could be mimicked by treatment with palmitoyl-CoA.
  • Moreover, inhibition of lipogenesis prevented monosaccharide-induced downregulation of HNF-4alpha and reduced SHBG expression in HepG2 cells.
  • This provides a biological explanation for why SHBG is a sensitive biomarker of the metabolic syndrome and the metabolic disturbances associated with increased fructose consumption.
  • [MeSH-minor] Adult. Animals. Biomarkers / blood. Cell Line, Tumor. Chickens / genetics. Child. Child, Preschool. Gene Expression Regulation / drug effects. Gene Expression Regulation / genetics. Gonadal Steroid Hormones / blood. Hepatocyte Nuclear Factor 1-alpha / genetics. Hepatocyte Nuclear Factor 1-alpha / metabolism. Humans. Metabolic Syndrome X / blood. Metabolic Syndrome X / genetics. Metabolic Syndrome X / pathology. Mice. Mice, Transgenic. Overweight / blood. Overweight / genetics. Overweight / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Nutr. 2004 Apr;79(4):537-43 [15051594.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2005 Oct;113(9):522-8 [16235154.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2963-72 [15181085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10715-20 [15235125.001]
  • [Cites] Steroidologia. 1970;1(3):129-36 [4107176.001]
  • [Cites] Diabetes Care. 1999 Nov;22(11):1875-81 [10546023.001]
  • [Cites] J Pediatr Endocrinol Metab. 2000;13 Suppl 5:1277-9 [11117669.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(21):7320-30 [11585914.001]
  • [Cites] Am J Clin Nutr. 2002 Jul;76(1):239-44 [12081841.001]
  • [Cites] J Lipid Res. 2002 Sep;43(9):1529-36 [12235185.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):37973-6 [12193589.001]
  • [Cites] Am J Clin Nutr. 2002 Nov;76(5):911-22 [12399260.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45291-8 [12235141.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28547-52 [12759350.001]
  • [Cites] Clin Endocrinol (Oxf). 1980 Apr;12(4):363-9 [6769612.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Mar;52(3):404-8 [7193218.001]
  • [Cites] Clin Chim Acta. 1983 Jul 31;132(1):101-10 [6193907.001]
  • [Cites] Clin Chem. 1986 Jan;32(1 Pt 1):146-52 [3940696.001]
  • [Cites] Metabolism. 1988 Jul;37(7):683-8 [3290626.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Sep;67(3):460-4 [2842359.001]
  • [Cites] Arteriosclerosis. 1989 Jan-Feb;9(1):136-43 [2643424.001]
  • [Cites] Pancreas. 1989;4(1):2-9 [2654926.001]
  • [Cites] Diabetes. 1991 Jan;40(1):123-8 [2015967.001]
  • [Cites] Am J Clin Nutr. 1993 Mar;57(3):319-22 [8438764.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):56-60 [8325960.001]
  • [Cites] Mol Cell Biol. 1993 Dec;13(12):7725-33 [8246989.001]
  • [Cites] FASEB J. 1994 Jan;8(1):28-35 [8299888.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):160-4 [7829605.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1283-9 [7536204.001]
  • [Cites] J Nutr. 1995 Sep;125(9):2286-93 [7666244.001]
  • [Cites] Am J Physiol. 1996 Apr;270(4 Pt 1):G541-53 [8928783.001]
  • [Cites] Horm Res. 1996;45(3-5):233-7 [8964590.001]
  • [Cites] Nature. 1996 Dec 5;384(6608):458-60 [8945471.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):235-40 [9435448.001]
  • [Cites] Mol Endocrinol. 1998 Jan;12(1):123-36 [9440816.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Nov;90(11):6275-82 [16131577.001]
  • [Cites] Circulation. 2005 Nov 15;112(20):3066-72 [16275870.001]
  • [Cites] J Nutr. 2006 Oct;136(10):2558-61 [16988126.001]
  • [Cites] Nature. 1998 Apr 2;392(6675):512-6 [9548258.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):16621-9 [9632736.001]
  • [Cites] J Biol Chem. 1998 Dec 18;273(51):34105-14 [9852068.001]
  • [Cites] Biol Pharm Bull. 1999 Sep;22(9):988-9 [10513628.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4462-8 [15574421.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1550-6 [15613437.001]
  • [Cites] Circulation. 2005 Mar 15;111(10):1242-9 [15769764.001]
  • [Cites] Diabetes Care. 2004 May;27(5):1036-41 [15111517.001]
  • (PMID = 17992261.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Gonadal Steroid Hormones; 0 / HNF1A protein, human; 0 / HNF4A protein, human; 0 / Hepatocyte Nuclear Factor 1-alpha; 0 / Hepatocyte Nuclear Factor 4; 0 / Hnf1a protein, mouse; 0 / Sex Hormone-Binding Globulin; 0 / Sweetening Agents; 30237-26-4 / Fructose; IY9XDZ35W2 / Glucose
  • [Other-IDs] NLM/ PMC2066187
  •  go-up   go-down


12. Kayed H, Jiang X, Keleg S, Jesnowski R, Giese T, Berger MR, Esposito I, Löhr M, Friess H, Kleeff J: Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br J Cancer; 2007 Oct 22;97(8):1106-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer.
  • In the present study, the localisation of the Runt-related transcription factor-2 (Runx2), its transcriptional activity, as well as its regulation of expression was analysed in human pancreatic ductal adenocarcinoma (PDAC).
  • Runt-related transcription factor-2 expression was silenced using specific siRNA oligonucleotides in pancreatic cancer cells (Panc-1) and immortalised pancreatic stellate cells (IPSCs).
  • There was a 6.1-fold increase in median Runx2 mRNA levels in PDAC tissues compared to normal pancreatic tissues (P<0.0001).
  • Runt-related transcription factor-2 was localised in pancreatic cancer cells, tubular complexes, and PanIN lesions of PDAC tissues as well as in tumour-associated fibroblasts/stellate cells.
  • Coculture of IPSCs and Panc-1 cells, as well as treatment with TGF-beta1 and BMP2, led to increased Runx2 expression in Panc-1 cells.
  • Runt-related transcription factor-2 overexpression was associated with decreased MMP1 release as well as decreased growth and invasion of Panc-1 cells.
  • In addition, Runx2 has the potential to regulate the transcription of extracellular matrix modulators such as SPARC and MMP1, thereby influencing the tumour microenvironment.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Core Binding Factor Alpha 1 Subunit / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Enzyme-Linked Immunosorbent Assay. Gene Expression. Humans. Immunohistochemistry. Matrix Metalloproteinase 1 / biosynthesis. RNA, Messenger / analysis. RNA, Small Interfering. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 2.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2004 Jul 5;166(1):85-95 [15226309.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):221-8 [15386419.001]
  • [Cites] Exp Cell Res. 2004 Sep 10;299(1):128-36 [15302580.001]
  • [Cites] Nucleic Acids Res. 2004;32(15):4609-17 [15333693.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Diabetes. 1993 May;42(5):746-56 [8482432.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2704-7 [8389240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6859-63 [8341710.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1846-56 [8253361.001]
  • [Cites] Genomics. 1994 Sep 15;23(2):425-32 [7835892.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):407-13 [7635566.001]
  • [Cites] Cell. 1997 May 30;89(5):755-64 [9182763.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2297-307 [10713153.001]
  • [Cites] Int J Cancer. 2000 May 1;86(3):399-407 [10760829.001]
  • [Cites] Gene. 2001 Nov 14;279(1):91-7 [11722849.001]
  • [Cites] Mol Carcinog. 2005 Apr;42(4):183-92 [15754313.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3790-8 [15897578.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4421-32 [15856026.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):224-34 [16041213.001]
  • [Cites] Cancer Biol Ther. 2005 Jul;4(7):740-6 [15970685.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(19):8581-91 [16166639.001]
  • [Cites] Lab Invest. 2005 Oct;85(10):1276-91 [16127427.001]
  • [Cites] Hepatology. 2005 Oct;42(4):935-45 [16175601.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2166-76 [16208410.001]
  • [Cites] Gene. 2006 Jan 17;366(1):58-66 [16325352.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2195-201 [16489021.001]
  • [Cites] Int J Mol Med. 2006 May;17(5):761-7 [16596258.001]
  • [Cites] Gene. 2006 May 10;372:62-70 [16574347.001]
  • [Cites] J Biol Chem. 2006 Jun 16;281(24):16347-53 [16613857.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6512-20 [16818622.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):18973-82 [16670084.001]
  • [Cites] J Cell Biochem. 2006 Nov 1;99(4):1108-21 [16767703.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5B):3633-43 [17094378.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):171-83 [16488077.001]
  • [Cites] Lung Cancer. 2007 Oct;58(1):131-8 [17606310.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23):6877-88 [11726523.001]
  • [Cites] Nucleic Acids Res. 2002 Apr 15;30(8):1757-66 [11937629.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6222-33 [12167715.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36181-7 [12110689.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7156-63 [12370805.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2002 Oct;12(5):301-9 [12477280.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7181-5 [12499254.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 15;31(2):589-95 [12527766.001]
  • [Cites] J Cell Biochem. 2003 Feb 15;88(3):493-505 [12532326.001]
  • [Cites] Prostate. 2003 Jun 15;56(1):13-22 [12746842.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2631-7 [12750290.001]
  • [Cites] Nucleic Acids Res. 2003 Jun 1;31(11):2705-16 [12771196.001]
  • [Cites] J Cell Biol. 2003 Sep 1;162(5):833-42 [12952936.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):294-9 [14990603.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2401-7 [14743205.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4924-9 [15044690.001]
  • [Cites] Genes Dev. 2004 Apr 15;18(8):952-63 [15107406.001]
  • [Cites] Mol Cancer Res. 2004 Apr;2(4):215-24 [15140943.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):668-76 [15146555.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4211-9 [15156175.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4315-29 [15156188.001]
  • [Cites] Cell. 1997 May 30;89(5):773-9 [9182765.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Aug 18;237(2):465-9 [9268735.001]
  • [Cites] Pancreas. 1998 Aug;17(2):169-75 [9700949.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):1025-36 [10215629.001]
  • [Cites] Gastroenterology. 1999 May;116(5):1202-16 [10220513.001]
  • [Cites] Development. 1999 Jul;126(13):2911-20 [10357935.001]
  • [Cites] Mol Cancer. 2003 Sep 17;2:32 [14521721.001]
  • (PMID = 17876328.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 1 Subunit; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / RUNX2 protein, human; EC 3.4.24.7 / Matrix Metalloproteinase 1
  • [Other-IDs] NLM/ PMC2360444
  •  go-up   go-down


13. Sandoval J, Pereda J, Rodriguez JL, Escobar J, Hidalgo J, Joosten LA, Franco L, Sastre J, López-Rodas G: Ordered transcriptional factor recruitment and epigenetic regulation of tnf-alpha in necrotizing acute pancreatitis. Cell Mol Life Sci; 2010 May;67(10):1687-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ordered transcriptional factor recruitment and epigenetic regulation of tnf-alpha in necrotizing acute pancreatitis.
  • Tauhe expression of the critical initiator cytokine TNF-alpha was strongly upregulated in vivo in acute necrotic pancreatitis (AP) in rodents and in vitro in TNF-alpha activated acinar AR42J cells.
  • Upregulation of tnf-alpha, inos, icam-1 and il-6 occurred both in TNF-alpha receptor 1 and 2 knock-out mice, but not in TNF-alpha knock-out mice, in cerulein-induced acute pancreatitis.
  • Activation of tnf-alpha gene was also accompanied by an ordered increased level of histone H3K9, H3K14 and H3K18-acetylation and H3K4 methylation, as well as H4K5 acetylation.
  • A better knowledge of the molecular mechanisms that control tnf-alpha gene regulation will provide deeper understanding of the initiation and development of the inflammatory processes occurring in acute pancreatitis triggered by TNF-alpha cytokine.
  • [MeSH-major] Epigenesis, Genetic. Pancreatitis, Acute Necrotizing / genetics. Transcription Factors / metabolism. Tumor Necrosis Factor-alpha / genetics
  • [MeSH-minor] Animals. Cell Line. Chromatin Immunoprecipitation. Histones / metabolism. Inflammation Mediators / metabolism. Mice. Mice, Inbred C57BL. Mice, Knockout. Promoter Regions, Genetic / genetics. Protein Processing, Post-Translational. Rats. Receptors, Tumor Necrosis Factor, Type I / deficiency. Receptors, Tumor Necrosis Factor, Type I / metabolism. Receptors, Tumor Necrosis Factor, Type II / deficiency. Receptors, Tumor Necrosis Factor, Type II / metabolism. Taurocholic Acid. Up-Regulation / genetics

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. TAUROCHOLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1985 May;88(5 Pt 1):1192-204 [2984080.001]
  • [Cites] Can J Gastroenterol. 2007 Jan;21(1):19-24 [17225878.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 20;359(1):88-93 [17532302.001]
  • [Cites] J Biol Chem. 1995 Aug 11;270(32):18966-74 [7642556.001]
  • [Cites] Crit Rev Immunol. 2009;29(2):131-54 [19496744.001]
  • [Cites] Drugs. 2001;61(11):1581-91 [11577795.001]
  • [Cites] J Clin Invest. 2007 Jun;117(6):1502-13 [17525799.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3925-9 [10760264.001]
  • [Cites] Am Surg. 1996 Jan;62(1):8-13 [8540653.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2830-4 [1849278.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):726-31 [16614115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2703-8 [17301242.001]
  • [Cites] Mol Cell. 1998 Jan;1(2):277-87 [9659924.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):1127-51 [17383433.001]
  • [Cites] Nucleic Acids Res. 2004 Jun 24;32(11):e88 [15247321.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2239-47 [10688670.001]
  • [Cites] J Neurosci Res. 2005 Dec 1;82(5):701-16 [16267827.001]
  • [Cites] Am J Surg. 1998 Jan;175(1):76-83 [9445247.001]
  • [Cites] Gene. 2003 Aug 14;313:43-57 [12957376.001]
  • [Cites] Biochem Pharmacol. 2006 Oct 30;72(9):1114-31 [16934762.001]
  • [Cites] Mol Cell Biol. 1990 May;10(5):2327-34 [2183031.001]
  • [Cites] Biochem J. 2006 Sep 15;398(3):431-7 [16776654.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):18091-7 [14976218.001]
  • [Cites] Curr Opin Struct Biol. 2008 Apr;18(2):236-42 [18206362.001]
  • [Cites] Gastroenterology. 1997 Nov;113(5):1741-6 [9352880.001]
  • [Cites] J Clin Invest. 1997 Oct 1;100(7):1853-62 [9312187.001]
  • [Cites] J Immunol. 2002 Jan 15;168(2):861-8 [11777983.001]
  • [Cites] FASEB J. 2001 Apr;15(6):893-7 [11292648.001]
  • [Cites] J Trauma. 2004 Feb;56(2):442-9 [14960994.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Mar;86(5):1490-4 [2537976.001]
  • [Cites] J Pharmacol Exp Ther. 2000 May;293(2):670-6 [10773043.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2218-29 [9528793.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11641-5 [7972116.001]
  • [Cites] Chest. 2003 Dec;124(6):2341-51 [14665518.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Sep;22(5):481-6 [16891878.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Apr;87(8):3127-31 [2158104.001]
  • [Cites] N Engl J Med. 1996 Jun 27;334(26):1717-25 [8637518.001]
  • [Cites] Front Biosci. 2002 Jan 01;7:d275-87 [11779694.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):1255-67 [15313424.001]
  • [Cites] J Pathol. 2000 Feb;190(2):117-25 [10657008.001]
  • [Cites] Oncogene. 1996 Jan 4;12(1):1-9 [8552378.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):214-8; discussion 218-9 [8311136.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2054-64 [12673210.001]
  • [Cites] Curr Med Chem. 2006;13(23):2775-87 [17073628.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6084-94 [10913190.001]
  • [Cites] J Clin Gastroenterol. 2000 Jun;30(4):343-56 [10875461.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):108-16 [15213626.001]
  • [Cites] Pancreas. 2007 Jan;34(1):1-14 [17198179.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):639-42 [8566616.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4770-7 [12471036.001]
  • [Cites] EMBO J. 2003 Jan 15;22(2):281-91 [12514134.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):651-60 [12403783.001]
  • [Cites] Curr Opin Genet Dev. 2001 Apr;11(2):205-8 [11250145.001]
  • (PMID = 20130956.001).
  • [ISSN] 1420-9071
  • [Journal-full-title] Cellular and molecular life sciences : CMLS
  • [ISO-abbreviation] Cell. Mol. Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Histones; 0 / Inflammation Mediators; 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Transcription Factors; 0 / Tumor Necrosis Factor-alpha; 5E090O0G3Z / Taurocholic Acid
  •  go-up   go-down


1
Advertisement
4. Qian ZY, Miao Y, Dai CC, Xu ZK, Liu XL: [Combined multiple organ resection in 16 patients with adenocarcinoma of the body or tail of the pancreas]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct;27(5):572-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined multiple organ resection in 16 patients with adenocarcinoma of the body or tail of the pancreas].
  • OBJECTIVE: To investigate the feasibility and therapeutic results of multiple organ resection in patients with tumor of the body and tail of pancreas.
  • METHODS: The clinical and pathological data were analysed in 16 consecutive patients with neoplasm of the body and tail of pancreas from 1999 to 2004 retrospectively.
  • RESULTS: Multiple organ resection was performed in 6 cases of primary pancreatic adenocarcinoma of the body and tail (3 cases of pancreatic cancer, 2 cases of malignant glucagonoma, and 1 case of well-differentiated pancreatic stromal sarcoma) and 10 cases of extrapancreatic malignancy (4 cases of gastric cancer, 2 cases of gastric leiomyosarcoma, 1 case of duodenal cancer, and 3 cases of colon cancer of hepatic flexure).
  • Patients with primary pancreatic cancer or pancreatic stromal sarcoma died within 1 year.
  • Two patients with malignant glucagonoma died 51 and 39 months later.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274034.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Lin YC, Lee PH, Yao YT, Hsiao JK, Sheu JC, Chen CH: Alpha-fetoprotein-producing pancreatic acinar cell carcinoma. J Formos Med Assoc; 2007 Aug;106(8):669-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein-producing pancreatic acinar cell carcinoma.
  • A 47-year-old man with chronic hepatitis B had progressive elevated alpha-fetoprotein of 2 years' duration.
  • A pancreatic tail tumor, instead of liver tumor, was detected.
  • He underwent elective distal pancreatectomy and splenectomy and the pathology turned out to be acinar cell carcinoma of the pancreas.
  • Serum level of alpha-fetoprotein returned to normal soon after surgery.
  • Alpha-fetoprotein is commonly used as a tumor marker to screen for hepatocellular carcinoma in high-risk patients.
  • However, elevated alpha-fetoprotein could occur in a much rarer disease, acinar cell carcinoma of the pancreas.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711801.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


16. Stoeltzing O, Liu W, Fan F, Wagner C, Stengel K, Somcio RJ, Reinmuth N, Parikh AA, Hicklin DJ, Ellis LM: Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system. Cancer Lett; 2007 Dec 18;258(2):291-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system.
  • Both the insulin-like growth factor-I receptor (IGF-IR) and cyclooxygenase-2 (COX-2) are frequently overexpressed in pancreatic cancer.
  • Pancreatic cancer cells (L3.6pl) were stably transfected with a dominant-negative receptor (IGF-IR DN) construct or empty vector (pcDNA).
  • Cells were stimulated with IGF-I to determine activated signaling intermediates and induction of COX-2.
  • In addition, IGF-IR DN cells showed a marked decrease in constitutive COX-2 and a blunted response to IGF-I.
  • Similarly, treatment with an anti-IGF-IR antibody effectively inhibited IGF-IR and MAPK/Erk activation and decreased COX-2 in parental cells.
  • In conclusion, activation of IGF-IR mediates COX-2 expression in human pancreatic cancer cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Jan 15;61(2):589-93 [11212254.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3065-74 [15837762.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] Neoplasia. 2001 Sep-Oct;3(5):428-36 [11687954.001]
  • [Cites] Oncogene. 2001 Dec 13;20(57):8203-14 [11781836.001]
  • [Cites] Pancreatology. 2001;1(4):291-9 [12120207.001]
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):194-201 [12162677.001]
  • [Cites] Curr Cancer Drug Targets. 2002 Sep;2(3):191-207 [12188907.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3259-69 [12374697.001]
  • [Cites] Lab Invest. 2002 Oct;82(10):1377-89 [12379772.001]
  • [Cites] J Cell Physiol. 2003 Feb;194(2):108-16 [12494449.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7372-6 [12499282.001]
  • [Cites] Mol Cancer Ther. 2003 Jan;2(1):1-7 [12533667.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):627-35 [12566306.001]
  • [Cites] Cancer Biol Ther. 2004 Dec;3(12):1217-24 [15477758.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4755-65 [16899627.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):1-12 [17237261.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3632-6 [12839952.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1001-11 [12937141.001]
  • [Cites] Cancer Biol Ther. 2003 Nov-Dec;2(6):630-5 [14688466.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8912-21 [14695208.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):802-8 [14710361.001]
  • [Cites] J Am Coll Surg. 2004 Sep;199(3):428-35 [15325613.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6549-55 [15374967.001]
  • [Cites] Br J Cancer. 1977 Jun;35(6):881-4 [871372.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2181-5 [8134369.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2007-11 [7743492.001]
  • [Cites] Gastroenterology. 1995 Jul;109(1):285-301 [7797026.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1128-33 [10534157.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7908-16 [10630643.001]
  • [Cites] Neoplasia. 1999 Apr;1(1):50-62 [10935470.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6045-51 [11085526.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5517-24 [11114729.001]
  • [Cites] J Cell Physiol. 1995 Oct;165(1):155-63 [7559796.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Biochim Biophys Acta. 1997 Jun 7;1332(3):F105-26 [9196021.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25693-9 [9325293.001]
  • [Cites] Br J Cancer. 1999 Sep;81(2):194-202 [10496342.001]
  • [Cites] Pancreas. 2001 Apr;22(3):293-8 [11291932.001]
  • (PMID = 17950526.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA009599-15; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA16672; United States / PHS HHS / / T-32 09599; United States / NCI NIH HHS / CA / T32 CA009599-15; United States / NCI NIH HHS / CA / T32 CA009599
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Enzyme Inhibitors; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 67763-96-6 / Insulin-Like Growth Factor I; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ NIHMS35362; NLM/ PMC2147684
  •  go-up   go-down


17. Long YM, Chen K, Liu XJ, Xie WR, Wang H: Cell-permeable Tat-NBD peptide attenuates rat pancreatitis and acinus cell inflammation response. World J Gastroenterol; 2009 Feb 7;15(5):561-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-permeable Tat-NBD peptide attenuates rat pancreatitis and acinus cell inflammation response.
  • AIM: To investigate the effects of Tat-NEMO-binding domain (NBD) peptide on taurocholate-induced pancreatitis and lipopolysaccharide (LPS)-stimulated AR42J acinus cells inflammatory response in rats.
  • The pancreatic histopathology was analyzed by hematoxylin staining.
  • LPS was added to the culture medium to stimulate the AR42J cells.
  • For pretreatment, cells were incubated with different peptides for 2 h before LPS stimulation.
  • Expression of IL-1beta and TNF-alpha mRNA was analyzed using a semi-quantitative reverse-transcript polymerase chain reaction (RT-PCR) method.
  • IL-1beta and TNF-alpha protein in culture medium were detected by enzyme linked immunosorbent assay (ELISA).
  • NF-kappaB DNA-binding in pancreas was examined by electrophoretic mobility shift assays.
  • LPS (10 mg/L) resulted in an increase of IL-1beta mRNA, IL-1beta protein, TNF-alpha mRNA and TNF-alpha protein, whereas significantly inhibitory effects were observed when cells were incubated with Tat-NBD (WT).
  • [MeSH-minor] Amino Acid Sequence. Amino Acid Substitution. Animals. Cell Line. Interleukin-1beta / genetics. NF-kappa B / physiology. Peptide Fragments / genetics. Peptide Fragments / therapeutic use. RNA, Messenger / genetics. Rats. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction. Taurocholic Acid / toxicity. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • Hazardous Substances Data Bank. TAUROCHOLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2002 Oct;195(4):497-505 [12375755.001]
  • [Cites] J Pathol. 2007 Nov;213(3):239-48 [17893879.001]
  • [Cites] Trends Pharmacol Sci. 2000 Feb;21(2):45-8 [10664605.001]
  • [Cites] Science. 2000 Sep 1;289(5484):1550-4 [10968790.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):7-11 [11134171.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jun;280(6):G1197-208 [11352813.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):448-57 [11832459.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45992-6000 [12244103.001]
  • [Cites] Gut. 2003 Feb;52(2):270-4 [12524412.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36676-87 [12867423.001]
  • [Cites] Trends Immunol. 2004 Jun;25(6):280-8 [15145317.001]
  • [Cites] J Biol Chem. 2004 Sep 3;279(36):37219-22 [15252035.001]
  • [Cites] Scand J Gastroenterol. 1980;15(4):411-6 [7433903.001]
  • [Cites] Cell. 1986 Aug 29;46(5):705-16 [3091258.001]
  • [Cites] Pathol Res Pract. 1989 May;184(5):507-13 [2748464.001]
  • [Cites] Yale J Biol Med. 1992 Sep-Oct;65(5):449-56; discussion 465-9 [1340062.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):664-8 [8290579.001]
  • [Cites] Am J Clin Pathol. 1996 May;105(5):589-98 [8623768.001]
  • [Cites] Crit Care Med. 1999 Apr;27(4):749-55 [10321665.001]
  • [Cites] World J Gastroenterol. 2005 Jul 21;11(27):4277-80 [16015706.001]
  • [Cites] Shock. 2005 Dec;24 Suppl 1:45-51 [16374372.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Aug;35(2):198-205 [16574946.001]
  • [Cites] Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii75-82 [17038479.001]
  • [Cites] Methods Mol Biol. 2000;130:235-46 [10589435.001]
  • (PMID = 19195057.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Gene Products, tat; 0 / Interleukin-1beta; 0 / NF-kappa B; 0 / Peptide Fragments; 0 / Peptides; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 5E090O0G3Z / Taurocholic Acid
  • [Other-IDs] NLM/ PMC2653342
  •  go-up   go-down


18. El-Rayes BF, Ali S, Philip PA, Sarkar FH: Protein kinase C: a target for therapy in pancreatic cancer. Pancreas; 2008 May;36(4):346-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein kinase C: a target for therapy in pancreatic cancer.
  • OBJECTIVES: Protein kinase C (PKC) is involved in tumor growth and apoptosis and hence represents a potential target for cancer therapy.
  • This study investigated the expression of PKC in pancreatic tumor tissue in comparison to adjacent normal tissue and determined the modulation of PKC by bryostatin-1 (BRYO) on pancreatic cancer cell lines.
  • METHODS: Pancreatic tissue was obtained from 18 patients who had a resection (14 with ductal adenocarcinoma and 4 with adenoma and high-grade dysplasia).
  • HPAC cells were treated with gemcitabine and BRYO and in sequential and concomitant combination.
  • To evaluate cell viability, apoptosis, and electrophoretic mobility shift assay, 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, enzyme-linked immunosorbent assay, and nuclear factor kappaB (NF-kappaB) assays were used.
  • RESULTS: As compared with the adjacent normal tissue, PKC-alpha, PKC-beta1, and PKC-delta were higher in the tumor; PKC-epsilon was higher in the normal tissue.
  • Pretreatment with gemcitabine followed by BRYO resulted in decreased cell viability, increased apoptosis, and inhibited NF-kappaB than either agent alone or BRYO followed by gemcitabine.
  • CONCLUSION: Protein kinase C is overexpressed and activated in pancreatic cancer as compared with normal tissue.
  • Inhibition of PKC could sensitize pancreatic cancer cell lines to the effects of gemcitabine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Isoenzymes / antagonists & inhibitors. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / enzymology. Protein Kinase C / antagonists & inhibitors
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenoma / drug therapy. Adenoma / enzymology. Adenoma / pathology. Bryostatins / administration & dosage. Cell Survival / drug effects. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Protein Kinase Inhibitors / therapeutic use. Reference Values

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437080.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bryostatins; 0 / Isoenzymes; 0 / Protein Kinase Inhibitors; 0W860991D6 / Deoxycytidine; 37O2X55Y9E / bryostatin 1; B76N6SBZ8R / gemcitabine; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


19. Marko PB, Miljković J, Zemljic TG: Necrolytic migratory erythema associated with hyperglucagonemia and neuroendocrine hepatic tumors. Acta Dermatovenerol Alp Pannonica Adriat; 2005 Dec;14(4):161-4, 166
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Necrolytic migratory erythema associated with hyperglucagonemia and neuroendocrine hepatic tumors.
  • The computed tomographic scan of the abdomen revealed multiple hepatic tumors.
  • Histopathological examination of ultrasound-guided needle biopsy from a hepatic lesion demonstrated a neuroendocrine tumor.
  • Somatostatin-receptor scintigraphy with radio-labelled octreotide confirmed the likelihood of the neuroendocrine nature of the hepatic tumors and excluded the presence of other such lesions throughout the rest of the body, including the pancreas.
  • The serum glucagon level was markedly increased.
  • The diagnosis of necrolytic migratory erythema associated with hyperglucagonemia and neuroendocrine hepatic tumors was made and therapy with the long-acting somatostatin analogue octreotide was started.
  • Having reached the final stage of the disease, which was further complicated by congestive heart failure, the patient died one year later.
  • As no autopsy was performed, we were unable to establish whether the hepatic tumors represented a metastatic process of previously undetected pancreatic glucagonoma or if they were extra-pancreatic glucagon-secreting tumors.
  • The correct diagnosis of necrolytic migratory erythema is important, since it might be the clue for early detection of glucagonoma or of extra-pancreatic glucagon-secreting tumors.
  • [MeSH-major] Dermatitis / etiology. Erythema / etiology. Liver Neoplasms / diagnosis. Neuroendocrine Tumors / diagnosis. Paraneoplastic Syndromes / diagnosis
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Glucagon / blood. Humans. Male. Middle Aged. Octreotide / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16435046.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 9007-92-5 / Glucagon; RWM8CCW8GP / Octreotide
  •  go-up   go-down


20. Grimsholm O, Rantapää-Dahlqvist S, Dalén T, Forsgren S: BDNF in RA: downregulated in plasma following anti-TNF treatment but no correlation with inflammatory parameters. Clin Rheumatol; 2008 Oct;27(10):1289-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, the effects of anti-tumour necrosis factor (anti-TNF; infliximab) treatment on BDNF levels in the plasma of RA patients were analysed.
  • Cells in the synovium showed immunoreactivity for BDNF and BDNF-, p75- and TrkB-receptor immunoreactions were seen in nerve fibres of nerve fascicles and in association with sensory corpuscles.
  • The levels of BDNF in synovial tissue were not correlated with the number of inflammatory cells observed microscopically or with levels of TNFalpha.
  • Nor did the BDNF levels in synovial fluid correlate with erythrocyte sedimentation rate (ESR) or white blood cell counts.
  • However, the levels of BDNF in plasma of patients treated with anti-TNF did not correlate with the changes in ESR or a disease activity score.
  • Instead it is likely that sources other than inflammatory cells, including nerve structures, are important sources of BDNF and that the effects of anti-TNF treatment on BDNF levels may be related to effects on circulating and various local cells and/or BDNF-containing neurons.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Arthritis, Rheumatoid / blood. Arthritis, Rheumatoid / drug therapy. Brain-Derived Neurotrophic Factor / blood. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Infliximab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Aug;119(2):368-76 [10930372.001]
  • [Cites] Acta Radiol Diagn (Stockh). 1968;:Suppl 277:7-72 [5706059.001]
  • [Cites] Anat Rec. 1993 Aug;236(4):730-6 [8379595.001]
  • [Cites] FASEB J. 2000 Oct;14(13):2097-107 [11023994.001]
  • [Cites] J Exp Med. 1999 Mar 1;189(5):865-70 [10049950.001]
  • [Cites] Neurosci Lett. 2005 Jul 1-8;382(1-2):148-52 [15911139.001]
  • [Cites] Ann Rheum Dis. 2005 Nov;64(11):1542-9 [15817657.001]
  • [Cites] Ann N Y Acad Sci. 2006 Jun;1069:438-43 [16855171.001]
  • [Cites] Ann Rheum Dis. 2005 Jan;64(1):13-20 [15608299.001]
  • [Cites] Inflamm Bowel Dis. 2007 Apr;13(4):398-409 [17206664.001]
  • [Cites] Clin Diagn Lab Immunol. 2003 Nov;10(6):1002-10 [14607859.001]
  • [Cites] Pancreas. 2002 Jul;25(1):31-8 [12131768.001]
  • [Cites] Anat Rec. 1997 Jul;248(3):433-41 [9214561.001]
  • [Cites] Clin Exp Rheumatol. 2003 Sep-Oct;21(5):617-24 [14611111.001]
  • [Cites] Cells Tissues Organs. 2004;177(1):47-54 [15237195.001]
  • [Cites] Arthritis Rheum. 1986 Aug;29(8):1039-49 [3741515.001]
  • [Cites] Acta Anat (Basel). 1990;139(2):154-60 [2288202.001]
  • [Cites] J Neuroimmunol. 2005 Mar;160(1-2):204-9 [15710474.001]
  • [Cites] Histochem J. 1995 Mar;27(3):222-30 [7541029.001]
  • [Cites] Brain Res Brain Res Rev. 2002 Oct;40(1-3):240-9 [12589922.001]
  • [Cites] Eur J Neurosci. 2003 Nov;18(9):2467-76 [14622147.001]
  • [Cites] J Orthop Res. 2005 Jul;23(4):757-63 [16022987.001]
  • [Cites] Arthritis Res Ther. 2006;8(6):220 [17118212.001]
  • [Cites] Arthritis Rheum. 1988 Mar;31(3):315-24 [3358796.001]
  • [Cites] Microsc Res Tech. 2006 Oct;69(10):808-19 [16830327.001]
  • [Cites] Neurosci Lett. 2003 Nov 27;352(1):49-52 [14615047.001]
  • [Cites] Arthritis Rheum. 1992 Mar;35(3):351-5 [1536673.001]
  • [Cites] Anat Rec. 1999 Jan;254(1):13-21 [9892413.001]
  • [Cites] Curr Opin Neurobiol. 2001 Jun;11(3):272-80 [11399424.001]
  • [Cites] Clin Chim Acta. 2005 Feb;352(1-2):49-74 [15653100.001]
  • [Cites] Rhinology. 2007 Jun;45(2):129-33 [17708459.001]
  • [Cites] Spine (Phila Pa 1976). 2004 Sep 1;29(17):1857-61 [15534405.001]
  • (PMID = 18484150.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Brain-Derived Neurotrophic Factor; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


21. Zhai Y, Qiao B, Shen XD, Gao F, Busuttil RW, Cheng G, Platt JL, Volk HD, Kupiec-Weglinski JW: Evidence for the pivotal role of endogenous toll-like receptor 4 ligands in liver ischemia and reperfusion injury. Transplantation; 2008 Apr 15;85(7):1016-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, we demonstrated that liver perfusates, generated by isolated liver perfusion system, contained LPS-independent, heat-sensitive protein molecules that activated macrophages to produce tumor necrosis factor (TNF)-alpha through TLR4 but not TLR2 pathway.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408583.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI023847; United States / NIAID NIH HHS / AI / AI42223; United States / NIAID NIH HHS / AI / AI23847; United States / NIAID NIH HHS / AI / R01 AI042223; United States / NIDDK NIH HHS / DK / R01 DK062357; United States / NIAID NIH HHS / AI / AI53733
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipopolysaccharides; 0 / Toll-Like Receptor 4
  •  go-up   go-down


22. Yang KC, Wu CC, Sumi S, Tseng CL, Wu YH, Kuo TF, Lin FH: Calcium phosphate cement chamber as an immunoisolative device for bioartificial pancreas: in vitro and preliminary in vivo study. Pancreas; 2010 May;39(4):444-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium phosphate cement chamber as an immunoisolative device for bioartificial pancreas: in vitro and preliminary in vivo study.
  • OBJECTIVES: This study examined a calcium phosphate cement (CPC) chamber as an immunoisolative device to facilitate the use of xenogeneic cell sources without immunosuppression for the bioartificial pancreas (BAP).
  • METHODS: Mouse insulinoma cells were encapsulated in agarose gel and then enclosed in a CPC chamber to create a BAP.
  • Bioartificial pancreas were evaluated by cell viability, live-dead cell ratio, and cytokine-mediated cytotoxicity assay and implanted into the peritoneal cavity of diabetic rats.
  • RESULTS: Insulinoma cells enclosed in the CPC chamber had normal viability, cell survival, and insulin secretion that was even cultured in media with cytokines.
  • Histological examination revealed the fibrous tissue envelopment, and immune-related cells that competed for oxygen resulting in hypoxia could be attributed to the dysfunction of BAPs.
  • An alternative implanted site should be considered to extend the functional longevity of BAPs in further study.
  • [MeSH-major] Artificial Organs. Calcium Phosphates / chemistry. Diabetes Mellitus, Experimental / metabolism. Pancreas / metabolism
  • [MeSH-minor] Animals. Blood Glucose / metabolism. Cell Culture Techniques / instrumentation. Cell Line, Tumor. Cell Survival / drug effects. Insulin / secretion. Insulinoma / metabolism. Insulinoma / pathology. Interleukin-1beta / pharmacology. Mice. Rats. Tumor Necrosis Factor-alpha / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084047.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Calcium Phosphates; 0 / Insulin; 0 / Interleukin-1beta; 0 / Tumor Necrosis Factor-alpha; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


23. Spee B, Jonkers MD, Arends B, Rutteman GR, Rothuizen J, Penning LC: Specific down-regulation of XIAP with RNA interference enhances the sensitivity of canine tumor cell-lines to TRAIL and doxorubicin. Mol Cancer; 2006;5:34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific down-regulation of XIAP with RNA interference enhances the sensitivity of canine tumor cell-lines to TRAIL and doxorubicin.
  • BACKGROUND: Apoptosis resistance occurs in various tumors.
  • Our aim is to evaluate whether RNA inhibition against XIAP increases the sensitivity of canine cell-lines for chemotherapeutics such as TRAIL and doxorubicin.
  • We used small interfering RNA's (siRNA) directed against XIAP in three cell-lines derived from bile-duct epithelia (BDE), mammary carcinoma (P114), and osteosarcoma (D17).
  • These cell-lines represent frequently occurring canine cancers and are highly comparable to their human counterparts.
  • The XIAP depleted cells were treated with a serial dilution of TRAIL or doxorubicin and compared to mock- and nonsense-treated controls.
  • RESULTS: All XIAP siRNA treated cell-lines showed a mRNA down-regulation over 80 percent.
  • No compensatory effect of IAP family members was seen in XIAP depleted cells.
  • The sensitivity of XIAP depleted cells for TRAIL was highest in BDE cells with an increase in the ED50 of 14-fold, compared to mock- and nonsense-treated controls.
  • The sensitivity of P114 and D17 cell-lines increased six- and five-fold, respectively.
  • Doxorubicin treatment in XIAP depleted cells increased sensitivity in BDE cells more than eight-fold, whereas P114 and D17 cell-lines showed an increase in sensitivity of three- and five-fold, respectively.
  • CONCLUSION: XIAP directed siRNA's have a strong sensitizing effect on TRAIL-reduced cell-viability and a smaller but significant effect with the DNA damaging drug doxorubicin.
  • The increase in efficacy of chemotherapeutics with XIAP depletion provides the rationale for the use of XIAP siRNA's in insensitive canine tumors.
  • [MeSH-major] Apoptosis Regulatory Proteins / pharmacology. Doxorubicin / pharmacology. Gene Expression Regulation, Neoplastic. Membrane Glycoproteins / pharmacology. RNA Interference. Tumor Necrosis Factor-alpha / pharmacology. X-Linked Inhibitor of Apoptosis Protein / genetics. X-Linked Inhibitor of Apoptosis Protein / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Dogs. Down-Regulation. Gene Expression Profiling. Homeostasis. Inhibitor of Apoptosis Proteins / classification. Inhibitor of Apoptosis Proteins / genetics. RNA, Messenger / genetics. Sensitivity and Specificity. TNF-Related Apoptosis-Inducing Ligand

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7797-802 [12810955.001]
  • [Cites] Pancreas. 2006 Apr;32(3):288-96 [16628085.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2826-36 [12855663.001]
  • [Cites] Int J Mol Med. 2003 Nov;12(5):705-8 [14532997.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4914-25 [14581366.001]
  • [Cites] Cancer Invest. 2000;18(8):781-92 [11107448.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3604-8 [11313486.001]
  • [Cites] Trends Biochem Sci. 2002 Feb;27(2):94-101 [11852247.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):554-60 [12384799.001]
  • [Cites] Curr Med Chem. 2003 Feb;10(3):245-56 [12570711.001]
  • [Cites] J Mol Biol. 2003 Apr 4;327(4):761-6 [12654261.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jun;4(6):457-67 [12778125.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8628-33 [14634624.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):725-31 [14644197.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):1-2 [14749118.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):25-35 [14749124.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3365-70 [15150085.001]
  • [Cites] Mol Cancer Ther. 2004 Jun;3(6):699-707 [15210856.001]
  • [Cites] Semin Cancer Biol. 2004 Aug;14(4):231-43 [15219616.001]
  • [Cites] J Biomater Sci Polym Ed. 2004;15(8):1033-49 [15461188.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1023-31 [15492788.001]
  • [Cites] Oncogene. 2004 Oct 21;23(49):8105-17 [15378029.001]
  • [Cites] Am J Vet Res. 1988 Nov;49(11):1903-5 [3247915.001]
  • [Cites] Am J Pathol. 1996 Mar;148(3):977-85 [8774152.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3737-44 [9042250.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):300-4 [9230442.001]
  • [Cites] J Drug Target. 2004 Jul;12(6):315-40 [15545082.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):532-8 [15685240.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1551-60 [15742333.001]
  • [Cites] Oncol Rep. 2005 Nov;14(5):1311-6 [16211302.001]
  • [Cites] Cell Death Differ. 2006 Feb;13(2):179-88 [16322751.001]
  • [Cites] Breast Cancer Res Treat. 2006 Apr;96(3):267-77 [16341821.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 2003 May;33(3):651-67 [12852241.001]
  • (PMID = 16953886.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Inhibitor of Apoptosis Proteins; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / X-Linked Inhibitor of Apoptosis Protein; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC1569868
  •  go-up   go-down


24. Steiner AA, Romanovsky AA: Leptin: at the crossroads of energy balance and systemic inflammation. Prog Lipid Res; 2007 Mar;46(2):89-107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In leptin-irresponsive mutants, the hypothermia of systemic inflammation is exaggerated, presumably due to the enhanced production and cryogenic action of tumor necrosis factor (TNF)-alpha.
  • The enhanced production of TNF-alpha and IL-1beta may be due, at least in part, to insufficient activation of the anti-inflammatory hypothalamo-pituitary-adrenal axis by immune stimuli in the absence of leptin signaling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Appl Physiol (1985). 2002 Jun;92(6):2667-79 [12015388.001]
  • [Cites] Am J Clin Nutr. 1998 Oct;68(4):794-801 [9771856.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]
  • [Cites] Physiol Behav. 1998 Jul;64(5):581-4 [9817566.001]
  • [Cites] Life Sci. 2005 Aug 12;77(13):1502-15 [15979653.001]
  • [Cites] Crit Care Med. 1998 Dec;26(12):1963-71 [9875905.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):207-12 [9874578.001]
  • [Cites] Endocrinology. 1999 Jan;140(1):138-45 [9886818.001]
  • [Cites] Am J Physiol. 1999 Jan;276(1 Pt 2):R136-42 [9887187.001]
  • [Cites] Physiol Rev. 1999 Jan;79(1):1-71 [9922367.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2002 Jan;282(1):R311-6 [11742853.001]
  • [Cites] Chest. 2001 Dec;120(6):1989-97 [11742933.001]
  • [Cites] Am J Physiol. 1998 Aug;275(2 Pt 2):R531-40 [9688690.001]
  • [Cites] Am J Physiol. 1998 Sep;275(3 Pt 2):R913-9 [9728091.001]
  • [Cites] Brain Res Bull. 1998 Aug;46(6):529-34 [9744290.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1311-4 [7489415.001]
  • [Cites] Am J Physiol. 1999 Mar;276(3 Pt 2):R864-71 [10070149.001]
  • [Cites] Neuroreport. 1999 Jan 18;10(1):153-6 [10094153.001]
  • [Cites] Nat Neurosci. 1998 Oct;1(6):445-50 [10196541.001]
  • [Cites] Crit Care Med. 1999 Apr;27(4):699-707 [10321658.001]
  • [Cites] Diabetes Obes Metab. 2005 Nov;7(6):755-61 [16219020.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2005 Nov;289(5):R1244-52 [16081879.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3651-9 [16258902.001]
  • [Cites] Diabetes. 1999 Feb;48(2):334-41 [10334310.001]
  • [Cites] Endocrinology. 1999 Jun;140(6):2755-62 [10342866.001]
  • [Cites] Neuroendocrinology. 1999 May;69(5):360-9 [10343177.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7047-52 [10359836.001]
  • [Cites] Pancreas. 1999 Jul;19(1):15-20 [10416686.001]
  • [Cites] J Infect Dis. 1999 Sep;180(3):908-11 [10438392.001]
  • [Cites] Endocrine. 1999 Jun;10(3):291-5 [10484293.001]
  • [Cites] J Physiol. 2004 Nov 15;561(Pt 1):263-72 [15388782.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3484-93 [16284652.001]
  • [Cites] Int J Obes (Lond). 2006 Jan;30(1):122-8 [16158086.001]
  • [Cites] Can J Physiol Pharmacol. 2005 Nov;83(11):1007-14 [16391709.001]
  • [Cites] Physiol Genomics. 2006 Apr 13;25(2):234-41 [16614459.001]
  • [Cites] Blood. 2006 May 15;107(10):4000-2 [16403908.001]
  • [Cites] Endocrinology. 2006 Jun;147(6):2886-92 [16556758.001]
  • [Cites] Eur J Neurosci. 2006 Jun;23(12):3359-67 [16820025.001]
  • [Cites] Neurol Clin. 2006 Aug;24(3):441-60 [16877117.001]
  • [Cites] PLoS One. 2006;1:e1 [17183631.001]
  • [Cites] Diabetes. 2004 Dec;53(12):3067-73 [15561935.001]
  • [Cites] FASEB J. 2004 Dec;18(15):1949-51 [15388670.001]
  • [Cites] Pediatr Crit Care Med. 2005 Jan;6(1):2-8 [15636651.001]
  • [Cites] Physiol Behav. 2005 Jan 31;84(1):165-73 [15642620.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2537-42 [15699332.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2005 Apr;288(4):R872-8 [15576666.001]
  • [Cites] J Immunol. 2005 Apr 15;174(8):4991-7 [15814729.001]
  • [Cites] Nat Neurosci. 2005 May;8(5):566-70 [15856064.001]
  • [Cites] J Intensive Care Med. 2005 May-Jun;20(3):147-54 [15888902.001]
  • [Cites] Front Biosci. 2005;10:2193-216 [15970487.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2005 Aug;289(2):R348-R352 [15860647.001]
  • [Cites] JAMA. 1999 Oct 27;282(16):1568-75 [10546697.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14623-8 [10588755.001]
  • [Cites] Endocrinology. 2000 Feb;141(2):560-3 [10650936.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1267-71 [10720074.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1781-7 [10793089.001]
  • [Cites] J Biol Chem. 2000 May 12;275(19):14563-72 [10799542.001]
  • [Cites] Annu Rev Physiol. 2000;62:413-37 [10845097.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 May;24(5):639-46 [10849588.001]
  • [Cites] J Comp Neurol. 2000 Jul 24;423(2):261-81 [10867658.001]
  • [Cites] Neuroendocrinology. 2000 Jun;71(6):375-85 [10878499.001]
  • [Cites] Neuroimmunomodulation. 2000;8(2):91-7 [10965234.001]
  • [Cites] Pflugers Arch. 2000 Oct;440(6):925-32 [11041560.001]
  • [Cites] Life Sci. 2000 Oct 6;67(20):2433-41 [11065166.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:647-57 [11268393.001]
  • [Cites] Br J Surg. 2001 Apr;88(4):588-93 [11298630.001]
  • [Cites] Int J Obes Relat Metab Disord. 2001 Apr;25(4):586-9 [11319666.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Jul;281(1):R115-32 [11404285.001]
  • [Cites] Neuro Endocrinol Lett. 2001 Jun;22(3):208-14 [11449193.001]
  • [Cites] Nutrition. 2001 Jul-Aug;17(7-8):664-8 [11448593.001]
  • [Cites] Am J Med. 2001 Sep;111(4):304-15 [11566461.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4593-9 [11591788.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):34-5 [11689931.001]
  • [Cites] FASEB J. 2001 Dec;15(14):2565-71 [11726531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14720-5 [11724949.001]
  • [Cites] Annu Rev Physiol. 2002;64:263-88 [11826270.001]
  • [Cites] Trends Neurosci. 2002 Mar;25(3):154-9 [11852148.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2391-4 [11994393.001]
  • [Cites] Funct Neurol. 2001;16(4 Suppl):205-16 [11996517.001]
  • [Cites] Nature. 2003 Feb 20;421(6925):856-9 [12594516.001]
  • [Cites] Int J Obes Relat Metab Disord. 2002 Apr;26(4):504-9 [12075577.001]
  • [Cites] J Clin Invest. 2002 Oct;110(8):1093-103 [12393845.001]
  • [Cites] J Nutr. 2002 Nov;132(11):3286-92 [12421841.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):885-91 [12490963.001]
  • [Cites] Curr Protein Pept Sci. 2005 Aug;6(4):327-353 [16101437.001]
  • [Cites] J Physiol. 2003 Mar 15;547(Pt 3):941-9 [12562931.001]
  • [Cites] Crit Care Med. 2003 Apr;31(4):1250-6 [12682500.001]
  • [Cites] N Engl J Med. 2003 Apr 17;348(16):1546-54 [12700374.001]
  • [Cites] Diabetes. 2003 Jun;52(6):1409-16 [12765951.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10085-90 [12897241.001]
  • [Cites] J Physiol. 2003 Sep 15;551(Pt 3):945-54 [12837930.001]
  • [Cites] Physiol Rev. 2004 Jan;84(1):277-359 [14715917.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1809-14 [14734764.001]
  • [Cites] Front Biosci. 2004 Jan 1;9:494-504 [14766385.001]
  • [Cites] J Am Soc Nephrol. 2004 Mar;15(3):645-9 [14978166.001]
  • [Cites] Br J Pharmacol. 2004 Apr;141(7):1204-13 [15006900.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 May;286(5):R832-7 [14742306.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4531-6 [15070752.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4661-6 [15070774.001]
  • [Cites] Mol Endocrinol. 2004 Jun;18(6):1354-62 [15016839.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Jul;287(1):R97-R103 [15191926.001]
  • [Cites] Diabetologia. 2004 Aug;47(8):1425-36 [15309293.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R992-5 [15191900.001]
  • [Cites] Science. 1975 Apr 11;188(4184):166-8 [1114347.001]
  • [Cites] Am J Clin Nutr. 1979 Mar;32(3):593-6 [283688.001]
  • [Cites] Acta Physiol Acad Sci Hung. 1979;53(3):265-77 [396758.001]
  • [Cites] Acta Physiol Acad Sci Hung. 1979;53(3):279-83 [396759.001]
  • [Cites] Infect Immun. 1980 Jun;28(3):771-6 [6772566.001]
  • [Cites] Am J Physiol. 1983 Feb;244(2):E145-50 [6297307.001]
  • [Cites] Biochem J. 1983 Jul 15;214(1):215-23 [6615467.001]
  • [Cites] Biol Neonate. 1983;44(5):309-14 [6357299.001]
  • [Cites] Am J Clin Nutr. 1984 Aug;40(2):310-6 [6465062.001]
  • [Cites] Annu Rev Immunol. 1983;1:335-59 [6399978.001]
  • [Cites] Physiol Behav. 1985 Dec;35(6):993-7 [4095193.001]
  • [Cites] Am J Physiol. 1986 Sep;251(3 Pt 2):R591-7 [3529990.001]
  • [Cites] Can J Physiol Pharmacol. 1987 Jun;65(6):1248-54 [3621073.001]
  • [Cites] Physiol Behav. 1987;41(2):179-85 [3685166.001]
  • [Cites] Am J Physiol. 1988 Apr;254(4 Pt 2):R633-40 [3258478.001]
  • [Cites] Am J Physiol. 1988 Jul;255(1 Pt 2):R157-65 [3394839.001]
  • [Cites] Experientia. 1988 Jul 15;44(7):606-7 [3396657.001]
  • [Cites] Physiol Behav. 1988;42(3):287-91 [3043484.001]
  • [Cites] Neurosci Biobehav Rev. 1988 Summer;12(2):123-37 [3050629.001]
  • [Cites] J Appl Physiol (1985). 1989 Sep;67(3):963-9 [2793726.001]
  • [Cites] J Physiol. 1989 Mar;410:367-80 [2795483.001]
  • [Cites] Physiol Behav. 1989 Sep;46(3):535-9 [2695950.001]
  • [Cites] Am J Physiol. 1990 Jul;259(1 Pt 2):R61-9 [2375430.001]
  • [Cites] Physiol Behav. 1990 May;47(5):963-91 [2201986.001]
  • [Cites] Physiol Rev. 1991 Jan;71(1):93-127 [1986393.001]
  • [Cites] Am J Physiol. 1991 Sep;261(3 Pt 2):R659-64 [1887952.001]
  • [Cites] Trends Pharmacol Sci. 1992 Jan;13(1):24-8 [1542935.001]
  • [Cites] Endocrinology. 1992 Apr;130(4):1931-41 [1312431.001]
  • [Cites] Crit Care Med. 1992 Jun;20(6):864-74 [1597042.001]
  • [Cites] Crit Care Med. 1992 Oct;20(10):1395-401 [1395659.001]
  • [Cites] J Immunol. 1993 Jul 1;151(1):436-48 [8326136.001]
  • [Cites] J Am Diet Assoc. 1993 Nov;93(11):1261-8 [7693786.001]
  • [Cites] Am J Physiol. 1994 Jan;266(1 Pt 2):R125-35 [8304533.001]
  • [Cites] Am J Physiol. 1994 Jan;266(1 Pt 2):R9-14 [8304560.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] Diabetes. 1995 Jul;44(7):855-8 [7789654.001]
  • [Cites] Nature. 1995 Oct 12;377(6549):527-9 [7566150.001]
  • [Cites] FEBS Lett. 1995 Oct 2;373(1):13-8 [7589424.001]
  • [Cites] Nat Med. 1995 Sep;1(9):953-6 [7585224.001]
  • [Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6957-60 [7624352.001]
  • [Cites] Science. 1995 Jul 28;269(5223):540-3 [7624776.001]
  • [Cites] Science. 1995 Jul 28;269(5223):543-6 [7624777.001]
  • [Cites] Am J Physiol. 1995 Jul;269(1 Pt 2):R23-9 [7631899.001]
  • [Cites] JAMA. 1995 Sep 27;274(12):968-74 [7674528.001]
  • [Cites] Am J Physiol. 1998 Jul;275(1 Pt 2):R323-31 [9688995.001]
  • [Cites] Am J Physiol. 1998 Jul;275(1 Pt 2):R332-8 [9688996.001]
  • [Cites] Diabetes. 1997 Mar;46(3):513-8 [9032111.001]
  • [Cites] Am J Physiol. 1997 Feb;272(2 Pt 2):R563-9 [9124479.001]
  • [Cites] Diabetes. 1999 Feb;48(2):279-86 [10334302.001]
  • [Cites] Am J Physiol. 1995 Nov;269(5 Pt 2):R1038-43 [7503289.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1263-71 [8548812.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] J Physiol. 1995 Nov 1;488 ( Pt 3):779-87 [8576867.001]
  • [Cites] Science. 1996 Feb 16;271(5251):994-6 [8584938.001]
  • [Cites] Cell. 1996 Feb 9;84(3):491-5 [8608603.001]
  • [Cites] Am J Physiol. 1996 Apr;270(4 Pt 2):R693-703 [8967396.001]
  • [Cites] Nature. 1996 Apr 25;380(6576):677 [8614460.001]
  • [Cites] J Clin Invest. 1996 May 1;97(9):2152-7 [8621806.001]
  • [Cites] Nature. 1996 Feb 15;379(6566):632-5 [8628397.001]
  • [Cites] Nat Genet. 1996 May;13(1):18-9 [8673096.001]
  • [Cites] Peptides. 1996;17(2):305-11 [8801538.001]
  • [Cites] Physiol Behav. 1996 Apr-May;59(4-5):787-93 [8778868.001]
  • [Cites] Diabetes. 1996 Aug;45(8):1141-3 [8690163.001]
  • [Cites] Am J Physiol. 1996 Jul;271(1 Pt 2):R244-53 [8760227.001]
  • [Cites] Genome Res. 1995 Aug;5(1):5-12 [8717050.001]
  • [Cites] FEBS Lett. 1996 Aug 26;392(2):87-90 [8772180.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3419-23 [8784108.001]
  • [Cites] Nat Genet. 1996 Oct;14(2):130-1 [8841178.001]
  • [Cites] Diabetes. 1996 Nov;45(11):1511-5 [8866554.001]
  • [Cites] Nutrition. 1996 May;12(5):303-15 [8875513.001]
  • [Cites] J Clin Invest. 1997 Jan 1;99(1):14-8 [9011568.001]
  • [Cites] J Exp Med. 1997 Jan 6;185(1):171-5 [8996253.001]
  • [Cites] J Biol Chem. 1997 Feb 14;272(7):4065-71 [9020115.001]
  • [Cites] J Clin Invest. 1997 Feb 1;99(3):385-90 [9022070.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2557-62 [9122234.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6093-6 [9102398.001]
  • [Cites] Ann N Y Acad Sci. 1997 Mar 15;813:733-7 [9100963.001]
  • [Cites] Brain Res. 1997 Mar 28;752(1-2):219-26 [9106460.001]
  • [Cites] Nature. 1997 May 8;387(6629):206-9 [9144295.001]
  • [Cites] Nature. 1997 Jun 26;387(6636):903-8 [9202122.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):270-8 [9218503.001]
  • [Cites] Am J Physiol. 1997 Jul;273(1 Pt 2):R113-20 [9249540.001]
  • [Cites] Am J Physiol. 1997 Jul;273(1 Pt 2):R181-6 [9249548.001]
  • [Cites] Am J Physiol. 1997 Jul;273(1 Pt 2):R407-13 [9249579.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jun;46(6):751-7 [9274707.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Sep;82(9):3084-6 [9284748.001]
  • [Cites] Endocrinology. 1998 Jan;139(1):8-19 [9421392.001]
  • [Cites] FASEB J. 1998 Jan;12(1):57-65 [9438411.001]
  • [Cites] Endocrinology. 1998 Feb;139(2):551-8 [9449624.001]
  • [Cites] Am J Physiol. 1998 Jan;274(1 Pt 2):R204-8 [9458919.001]
  • [Cites] Appetite. 1997 Dec;29(3):369-83 [9468766.001]
  • [Cites] Am J Physiol. 1998 Feb;274(2 Pt 2):R406-11 [9486298.001]
  • [Cites] Life Sci. 1998;62(10):923-36 [9496715.001]
  • [Cites] Nat Genet. 1998 Mar;18(3):213-5 [9500540.001]
  • [Cites] Int J Obes Relat Metab Disord. 1998 Feb;22(2):83-8 [9504315.001]
  • [Cites] Endocrinology. 1998 Apr;139(4):1524-32 [9528930.001]
  • [Cites] Infect Immun. 1998 Apr;66(4):1800-2 [9529118.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):398-401 [9537324.001]
  • [Cites] J Physiol. 1998 May 15;509 ( Pt 1):267-75 [9547399.001]
  • [Cites] Endocrinology. 1998 May;139(5):2278-83 [9564834.001]
  • [Cites] Med Hypotheses. 1998 Mar;50(3):213-8 [9578326.001]
  • [Cites] Med Hypotheses. 1998 Mar;50(3):219-26 [9578327.001]
  • [Cites] Am J Physiol. 1998 Jun;274(6 Pt 1):E992-7 [9611147.001]
  • (PMID = 17275915.001).
  • [ISSN] 0163-7827
  • [Journal-full-title] Progress in lipid research
  • [ISO-abbreviation] Prog. Lipid Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS041233-04; United States / NINDS NIH HHS / NS / R01 NS041233; United States / NINDS NIH HHS / NS / NS41233; United States / NINDS NIH HHS / NS / R01 NS041233-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Leptin
  • [Number-of-references] 209
  • [Other-IDs] NLM/ NIHMS23764; NLM/ PMC1976277
  •  go-up   go-down


25. de Herder WW: Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab; 2007 Mar;21(1):33-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemistry of neuroendocrine tumours.
  • Several circulating or urinary tumour markers can be used for the diagnosis and follow-up of functioning and clinically non-functioning neuroendocrine tumours of the pancreatic islet cells and intestinal tract.
  • Among the specific tumour markers are serotonin and its metabolites--e.g.
  • 5-hydroxyindoleacetic acid (5-HIAA)--in carcinoid tumours and the carcinoid syndrome, insulin and its precursors or breakdown products in insulinoma, and gastrin in gastrinoma.
  • Plasma vasointestinal polypeptide (VIP) determinations have been used in the diagnosis of VIPoma, plasma glucagon for glucagonoma, and serum somatostatin for somatostatinoma.
  • Among the tumour-non-specific markers are: chromogranins, neuron-specific enolase (NSE), alpha-subunits of the glycoprotein hormones, catecholamines, pancreatic polypeptide (PP), ghrelin and adrenomedullin.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neuroendocrine Tumors / diagnosis
  • [MeSH-minor] Biomarkers / analysis. Carcinoid Tumor / diagnosis. Gastrinoma / diagnosis. Gastrins / analysis. Humans. Insulin / analysis. Insulin / metabolism. Insulinoma / diagnosis. Malignant Carcinoid Syndrome / diagnosis. Pancreatic Neoplasms / diagnosis. Serotonin / analysis. Serotonin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382264.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Gastrins; 0 / Insulin; 333DO1RDJY / Serotonin
  • [Number-of-references] 49
  •  go-up   go-down


26. Kreutzer JN, Ruzzene M, Guerra B: Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells. BMC Cancer; 2010;10:440
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.
  • BACKGROUND: Pancreatic cancer is a complex genetic disorder that is characterized by rapid progression, invasiveness, resistance to treatment and high molecular heterogeneity.
  • Various agents have been used in clinical trials showing only modest improvements with respect to gemcitabine-based chemotherapy, which continues to be the standard first-line treatment for this disease.
  • However, owing to the overwhelming molecular alterations that have been reported in pancreatic cancer, there is increasing focus on targeting molecular pathways and networks, rather than individual genes or gene-products with a combination of novel chemotherapeutic agents.
  • METHODS: Cells were transfected with small interfering RNAs (siRNAs) targeting the individual CK2 subunits.
  • The CK2 protein expression levels were determined and the effect of its down-regulation on chemosensitization of pancreatic cancer cells was investigated.
  • RESULTS: The present study examined the impact on cell death following depletion of the individual protein kinase CK2 catalytic subunits alone or in combination with gemcitabine and the molecular mechanisms by which this effect is achieved.
  • Depletion of the CK2alpha or -alpha' subunits in combination with gemcitabine resulted in marked apoptotic and necrotic cell death in PANC-1 cells.
  • We show that the mechanism of cell death is associated with deregulation of distinct survival signaling pathways.
  • CONCLUSIONS: Results reported here show that the two catalytic subunits of CK2 contribute differently to enhance gemcitabine-induced cell death, the reduced level of CK2alpha' being the most effective and that simultaneous reduction in the expression of CK2 and other survival factors might be an effective therapeutic strategy for enhancing the sensitivity of human pancreatic cancer towards chemotherapeutic agents.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Pancreatic Ductal / drug therapy. Casein Kinase II / antagonists & inhibitors. Casein Kinase II / genetics. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. RNA, Small Interfering / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Cell Proliferation / drug effects. Humans. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(3):908-15 [12529396.001]
  • [Cites] FASEB J. 2003 Mar;17(3):349-68 [12631575.001]
  • [Cites] Biochem Pharmacol. 2003 Aug 1;66(3):459-69 [12907245.001]
  • [Cites] Cell. 1994 Mar 25;76(6):1025-37 [8137421.001]
  • [Cites] Genes Dev. 1994 Dec 15;8(24):2996-3007 [8001819.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1326-31 [7481820.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3636-41 [8622988.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Aug 23;225(3):968-74 [8780719.001]
  • [Cites] Int J Pancreatol. 1997 Oct;22(2):81-93 [9387029.001]
  • [Cites] Mol Carcinog. 1998 Feb;21(2):81-6 [9496907.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):391-408 [10197447.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3581-7 [10446965.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):118-21 [10471512.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):668-77 [15818404.001]
  • [Cites] Trends Mol Med. 2005 Aug;11(8):353-61 [16002336.001]
  • [Cites] Mol Cell Biochem. 2005 Jun;274(1-2):3-14 [16335523.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1218-49 [16702400.001]
  • [Cites] Protein Expr Purif. 2006 Jun;47(2):651-61 [16442308.001]
  • [Cites] J Surg Res. 2001 May 15;97(2):123-30 [11341787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6 [11717429.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3754-64 [12032843.001]
  • [Cites] FASEB J. 2006 Oct;20(12):1982-91 [17012250.001]
  • [Cites] Oncol Rep. 2007 Sep;18(3):695-701 [17671722.001]
  • [Cites] Pancreas. 2007 Oct;35(3):e16-26 [17895832.001]
  • [Cites] Oncogene. 2007 Oct 18;26(48):6915-26 [17486073.001]
  • [Cites] Mol Cell Biol. 2008 Jan;28(1):131-9 [17954558.001]
  • [Cites] Int J Biol Sci. 2005;1(2):67-79 [15951851.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1784(1):33-47 [17931986.001]
  • [Cites] Curr Med Chem. 2008;15(19):1870-86 [18691045.001]
  • [Cites] Oncogene. 2008 Aug 28;27(37):4986-97 [18469858.001]
  • [Cites] Expert Opin Emerg Drugs. 2009 Jun;14(2):311-28 [19466902.001]
  • [Cites] Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):412-22 [19506583.001]
  • [Cites] Cell Mol Life Sci. 2009 Oct;66(20):3363-73 [19662498.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1487-97 [19828010.001]
  • [Cites] FEBS Lett. 1999 Dec 3;462(3):353-7 [10622724.001]
  • [Cites] Biochem J. 2003 Jan 1;369(Pt 1):1-15 [12396231.001]
  • (PMID = 20718998.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.11.1 / Casein Kinase II
  • [Other-IDs] NLM/ PMC2931491
  •  go-up   go-down


27. Park SJ, Seo SW, Choi OS, Park CS: Alpha-lipoic acid protects against cholecystokinin-induced acute pancreatitis in rats. World J Gastroenterol; 2005 Aug 21;11(31):4883-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-lipoic acid protects against cholecystokinin-induced acute pancreatitis in rats.
  • AIM: Alpha-lipoic acid (ALA) has been used as an antioxidant.
  • The aim of this study was to investigate the effect of alpha-lipoic acid on cholecystokinin (CCK)-octapeptide induced acute pancreatitis in rats.
  • We checked the pancreatic weight/body weight ratio, the secretion of pro-inflammatory cytokines and the levels of lipase, amylase of serum.
  • RESULTS: ALA significantly decreased the pancreatic weight/body weight ratio and serum amylase and lipase in CCK octapeptide-induced acute pancreatitis.
  • However, the secretion of IL-1beta, IL-6, and TNF-alpha were comparable in CCK octapeptide-induced acute pancreatitis.
  • [MeSH-minor] Acute Disease. Animals. Hyperlipidemias / prevention & control. Injections, Intraperitoneal. Interleukin-1 / secretion. Interleukin-6 / secretion. Male. Rats. Rats, Wistar. Tumor Necrosis Factor-alpha / secretion

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16097064.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 73Y7P0K73Y / Thioctic Acid; 9011-97-6 / Cholecystokinin
  • [Other-IDs] NLM/ PMC4398742
  •  go-up   go-down


28. Chaw L, Krop TM, Hood AF: What is your diagnosis? Necrolytic migratory erythema associated with a glucagonoma. Cutis; 2008 Jan;81(1):25, 30-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is your diagnosis? Necrolytic migratory erythema associated with a glucagonoma.
  • [MeSH-major] Erythema / etiology. Glucagonoma / complications. Pancreatic Neoplasms / complications. Paraneoplastic Syndromes / pathology. Skin / pathology. Skin Diseases / etiology
  • [MeSH-minor] Female. Glucagon / blood. Humans. Middle Aged

  • Genetic Alliance. consumer health - Glucagonoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306843.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-92-5 / Glucagon
  •  go-up   go-down


29. Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, Scarpa A, Rodolfo M, Knowles M, Frattini M, Marchetti A, Bardelli A: Mutational profile of GNAQQ209 in human tumors. PLoS One; 2009;4(8):e6833
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational profile of GNAQQ209 in human tumors.
  • BACKGROUND: Frequent somatic mutations have recently been identified in the ras-like domain of the heterotrimeric G protein alpha-subunit (GNAQ) in blue naevi 83%, malignant blue naevi (50%) and ocular melanoma of the uvea (46%).
  • METHODOLOGY: To assess if the mutations are present in other tumor types we performed a systematic mutational profile of the GNAQ exon 5 in a panel of 922 neoplasms, including glioblastoma, gastrointestinal stromal tumors (GIST), acute myeloid leukemia (AML), blue naevi, skin melanoma, bladder, breast, colorectal, lung, ovarian, pancreas, and thyroid carcinomas.
  • Changes affecting Q209 were not found in any of the other tumors.
  • Our data indicate that the occurrence of GNAQ mutations display a unique pattern being present in a subset of melanocytic tumors but not in malignancies of glial, epithelial and stromal origin analyzed in this study.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Dec 2;402(6761):496-501 [10591209.001]
  • [Cites] Oncogene. 2001 Mar 26;20(13):1607-14 [11313908.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):705-10 [15252839.001]
  • [Cites] Biochem Cell Biol. 2005 Feb;83(1):1-14 [15746962.001]
  • [Cites] Oncogene. 2008 Sep 18;27(42):5648-50 [18504432.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3545-50 [17440062.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):599-602 [19078957.001]
  • [Cites] Cell Signal. 2006 Feb;18(2):135-50 [16182515.001]
  • (PMID = 19718445.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.5.1 / Heterotrimeric GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2730032
  •  go-up   go-down


30. Seo DW: EUS-Guided Antitumor Therapy for Pancreatic Tumors. Gut Liver; 2010 Sep;4 Suppl 1:S76-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS-Guided Antitumor Therapy for Pancreatic Tumors.
  • Endoscopic ultrasound (EUS) is a very useful modality for the diagnosis and staging of pancreatic masses.
  • With the advent of EUS-guided fine-needle aspiration technology, this modality has made a tremendous leap from imaging modality to histologic diagnosis and therapeutic intervention.
  • EUS offers high-resolution images of and unparalleled access to the pancreas.
  • After locating the tip of the echoendoscope in the duodenum or stomach, several drugs or local treatment modalities can be delivered directly into the pancreas.
  • EUS-guided ethanol lavage with/without paclitaxel injection has been tested for the treatment of cystic tumors of the pancreas, with complete resolution of cystic tumor being observed in up to 70-80% of patients.
  • Ethanol injection is also performed for the management of solid neuroendocrine tumors of the pancreas.
  • Various type of EUS-guided injection have also been investigated for the treatment of pancreatic cancer.
  • An activated allogenic mixed lymphocyte culture (Cytoimplant) was injected in patients with advanced pancreatic cancer.
  • A replication-deficient adenovirus vector carrying the tumor necrosis factor-alpha gene was also delivered intratumorally by EUS.
  • ONYX-015 is an oncolytic attenuated adenovirus that exhibits replication preferentially in malignant cells, causing cell death, and this has also been injected into pancreatic cancers under EUS guidance.
  • This article reviews the various applications of EUS for the treatment of pancreatic tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):392-401 [10462663.001]
  • [Cites] Acta Radiol. 1997 Nov;38(6):993-7 [9394655.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1325-35 [10717613.001]
  • [Cites] Cancer Lett. 2002 Oct 8;184(1):37-47 [12104046.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):555-61 [12576418.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):746-52 [15855986.001]
  • [Cites] Endoscopy. 2006 Apr;38(4):399-403 [16680642.001]
  • [Cites] Gastrointest Endosc. 2006 Jun;63(7):1059-62 [16733126.001]
  • [Cites] Am J Surg. 2006 Aug;192(2):148-54 [16860621.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):572-82 [16998366.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):98-103 [17970834.001]
  • [Cites] Gastrointest Endosc. 2007 Dec;66(6):1201-5 [18061721.001]
  • [Cites] Gastrointest Endosc. 2008 May;67(6):957-61 [18178203.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2008 Feb;5(2):107-11 [18253139.001]
  • [Cites] Gastrointest Endosc. 2008 Apr;67(4):636-42 [18262182.001]
  • [Cites] Endoscopy. 2008 Apr;40(4):314-20 [18283622.001]
  • [Cites] Scand J Gastroenterol. 2009;44(2):242-7 [18949629.001]
  • [Cites] Gastrointest Endosc. 2009 Feb;69(2 Suppl):S54-8 [19179171.001]
  • [Cites] Pancreas. 2009 Apr;38(3):e69-74 [19276867.001]
  • [Cites] J Ultrasound Med. 1998 Aug;17(8):531-3 [9697961.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Apr;56(4):557-9 [11966750.001]
  • [Cites] Lancet. 1980 Mar 22;1(8169):629-31 [6102631.001]
  • [Cites] AJR Am J Roentgenol. 1980 Sep;135(3):627-9 [6773394.001]
  • [Cites] Endoscopy. 1980 Sep;12(5):241-4 [7428729.001]
  • [Cites] Radiology. 1981 Feb;138(2):329-31 [7455112.001]
  • [Cites] Int J Pancreatol. 1995 Dec;18(3):197-206 [8708390.001]
  • [Cites] AJR Am J Roentgenol. 1996 Sep;167(3):781-3 [8751700.001]
  • [Cites] Gastrointest Endosc. 1996 Dec;44(6):656-62 [8979053.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):269-74 [10587182.001]
  • (PMID = 21103299.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2989554
  • [Keywords] NOTNLM ; Brachytherapy / Cystic tumor / Cytoimplant / Endoscopic ultrasonography / Immunotherapy / Pancreas cancer / Photodynamic therapy / Radiofrequency ablation
  •  go-up   go-down


31. Song JM, Liu HX, Li Y, Zeng YJ, Zhou ZG, Liu HY, Xu B, Wang L, Zhou B, Wang R: Extracellular heat-shock protein 70 aggravates cerulein-induced pancreatitis through toll-like receptor-4 in mice. Chin Med J (Engl); 2008 Aug 5;121(15):1420-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In patients suffering from acute pancreatitis, the pathogenesis is not completely understood, and several recent studies in vitro suggested that heat shock proteins might play an important role in cell signaling.
  • Histologic alteration of the pancreas was evaluated.
  • Tumor necrosis factor alpha (TNF-alpha) concentrations and myeloperoxidase (MPO) activity in both pancreas and lungs were analyzed.
  • The nuclear factor kappa B (NF-kappaB) activation in pancreatic tissue was measured using a sensitive RelA enzyme-linked immunosorbent assay.
  • RESULTS: Treatment with recombinant Hsp70 to wild-type mice in CIP resulted in significant aggravation of inflammation in pancreas, elevated levels of serum cytokines, up-regulation of pulmonary MPO activity and increase of lung tissues TNF-alpha concentrations.
  • In contrast, treatment with Hsp70 to TLR4-deficient mice had little effect on serum cytokines levels, pancreatic inflammation, pulmonary MPO activity and TNF-alpha concentrations.
  • CONCLUSIONS: The results suggest that extracellular Hsp70 might induce systemic inflammatory response syndrome (SIRS)-like response in vivo and TLR4 might be involved in the Hsp70-mediated activation of inflammatory reaction in the progression of CIP without infection.
  • [MeSH-minor] Acute Disease. Animals. Female. Male. Mice. Mice, Inbred C57BL. Systemic Inflammatory Response Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18959120.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; 0 / Tlr4 protein, mouse; 0 / Toll-Like Receptor 4; 888Y08971B / Ceruletide
  •  go-up   go-down


32. Shen HC, Ylaya K, Pechhold K, Wilson A, Adem A, Hewitt SM, Libutti SK: Multiple endocrine neoplasia type 1 deletion in pancreatic alpha-cells leads to development of insulinomas in mice. Endocrinology; 2010 Aug;151(8):4024-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple endocrine neoplasia type 1 deletion in pancreatic alpha-cells leads to development of insulinomas in mice.
  • The pancreatic alpha- and beta-cells are critical components in regulating blood glucose homeostasis via secretion of glucagon and insulin, respectively.
  • Both cell types are typically localized in the islets of Langerhans.
  • The lack of suitable cell lines to study alpha- and beta-cells interactions have led us to develop an alpha-cell-specific Cre-expressing transgenic line utilizing a glucagon promoter sequence, the Glu-Cre transgenic mouse.
  • Here, we demonstrate that the Glu-Cre could specifically and efficiently excise floxed target genes in adult islet alpha-cells.
  • We further showed that deletion of the tumor suppressor gene, multiple endocrine neoplasia type 1 (Men1), in alpha-cells led to tumorigenesis.
  • However, to our surprise, the lack of Men1 in alpha-cells did not result in glucagonomas but rather beta-cell insulinomas.
  • Because deletion of the Men1 alleles was only present in alpha-cells, our data suggested that cross communication between alpha- and beta-cells contributes to tumorigenesis in the absence of Men1.
  • Together, we believed that the new model systems described here will allow future studies to decipher cellular interactions between islet alpha- and beta-cells in a physiological context.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCAGON .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2000 Jun;127(11):2317-22 [10804174.001]
  • [Cites] Gastroenterology. 2010 May;138(5):1954-65 [20138042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1118-23 [11158604.001]
  • [Cites] Endocrine. 2002 Dec;19(3):267-78 [12624426.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6075-85 [12917331.001]
  • [Cites] Mol Endocrinol. 2003 Sep;17(9):1880-92 [12819299.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4836-41 [12941803.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5320-8 [14500363.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):8022-8 [14633735.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3125-31 [15060136.001]
  • [Cites] Diabetes. 1982 Oct;31(10):883-9 [6759221.001]
  • [Cites] QJM. 1996 Sep;89(9):653-69 [8917740.001]
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] Hum Mol Genet. 1997 Jul;6(7):1177-83 [9215690.001]
  • [Cites] Ann Intern Med. 1998 Sep 15;129(6):484-94 [9735087.001]
  • [Cites] Dev Biol. 1999 Apr 15;208(2):281-92 [10191045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2334-9 [16461897.001]
  • [Cites] ILAR J. 2006;47(2):94-102 [16547366.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):259-67 [17044021.001]
  • [Cites] Endocr Rev. 2007 Feb;28(1):84-116 [17261637.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1858-66 [19208834.001]
  • [Cites] Methods Mol Biol. 2009;530:423-33 [19266333.001]
  • [Cites] PLoS One. 2009;4(4):e4897 [19340311.001]
  • [Cites] Diabetes. 2009 May;58(5):1175-84 [19228810.001]
  • [Cites] Nat Biotechnol. 2009 Nov;27(11):1038-42 [19838197.001]
  • [Cites] Br J Cancer. 2000 Oct;83(8):1003-8 [10993646.001]
  • (PMID = 20555035.001).
  • [ISSN] 1945-7170
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Men1 protein, mouse; 0 / Proto-Oncogene Proteins; 9007-92-5 / Glucagon
  • [Other-IDs] NLM/ PMC2940531
  •  go-up   go-down


33. Sato K, Arai H, Mizuno A, Fukaya M, Sato T, Koganei M, Sasaki H, Yamamoto H, Taketani Y, Doi T, Takeda E: Dietary palatinose and oleic acid ameliorate disorders of glucose and lipid metabolism in Zucker fatty rats. J Nutr; 2007 Aug;137(8):1908-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 8 wk, palatinose feeding (PO and PL) led to significant reductions in visceral fat mass, adipocyte cell size, hyperglycemia, and hyperlipidemia compared with sucrose feeding (SO and SL); pancreatic islet hypertrophy was also prevented by palatinose feeding.
  • Linoleic-acid-fed rats (PL and SL) exhibited reduced insulin-immunoreactive staining of the pancreatic islets, enhanced macrophage infiltration in adipose tissue, and an elevated plasma tumor necrosis factor-alpha concentration when compared with oleic-acid-fed rats (PO and SO).
  • [MeSH-minor] Adipose Tissue / drug effects. Adipose Tissue / pathology. Animals. Blood Glucose / drug effects. Body Weight. Gene Expression Regulation / drug effects. Inflammation / pathology. Liver / drug effects. Liver / metabolism. Male. Pancreas / drug effects. Rats. Rats, Zucker. Triglycerides / blood

  • Hazardous Substances Data Bank. OLEIC ACID .
  • Hazardous Substances Data Bank. GLUCOSE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634263.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Triglycerides; 2UMI9U37CP / Oleic Acid; 43360LXH8N / isomaltulose; 67I334IX2M / Isomaltose; IY9XDZ35W2 / Glucose
  •  go-up   go-down


34. Matsuda T, Almasan A, Tomita M, Uchihara JN, Masuda M, Ohshiro K, Takasu N, Yagita H, Ohta T, Mori N: Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines. J Virol; 2005 Feb;79(3):1367-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines.
  • Adult T-cell leukemia (ATL), a CD4+-T-cell malignancy caused by human T-cell leukemia virus type 1 (HTLV-1), is difficult to cure, and novel treatments are urgently needed.
  • Apo2 ligand (Apo2L; also tumor necrosis factor-related apoptosis-inducing ligand [TRAIL]) has been implicated in antitumor therapy.
  • We found that HTLV-1-infected T-cell lines and primary ATL cells were more resistant to Apo2L-induced apoptosis than uninfected cells.
  • Interestingly, HTLV-1-infected T-cell lines and primary ATL cells constitutively expressed Apo2L mRNA.
  • Inducible expression of the viral oncoprotein Tax in a T-cell line up-regulated Apo2L mRNA.
  • NF-kappaB plays a crucial role in the pathogenesis and survival of ATL cells.
  • [MeSH-major] Gene Expression Regulation. Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / pathogenicity. Membrane Glycoproteins / metabolism. NF-kappa B / metabolism. T-Lymphocytes / virology. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Apoptosis. Apoptosis Regulatory Proteins. Cell Line. Humans. Leukemia-Lymphoma, Adult T-Cell. Ligands. TNF-Related Apoptosis-Inducing Ligand. Transcriptional Activation

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1983 Feb 18;219(4586):856-9 [6600519.001]
  • [Cites] Blood. 1984 Aug;64(2):482-90 [6331549.001]
  • [Cites] Science. 1987 Sep 11;237(4820):1324-9 [2888190.001]
  • [Cites] Nucleic Acids Res. 1989 Feb 25;17(4):1589-604 [2784206.001]
  • [Cites] Leukemia. 1999 Nov;13(11):1817-24 [10557057.001]
  • [Cites] J Virol. 2000 Jan;74(1):556-9 [10590149.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6153-8 [10626806.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):553-9 [10676636.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):335-46 [10690508.001]
  • [Cites] J Immunol. 2000 Apr 15;164(8):3961-70 [10754286.001]
  • [Cites] Immunity. 1997 Dec;7(6):813-20 [9430226.001]
  • [Cites] Immunity. 1997 Dec;7(6):821-30 [9430227.001]
  • [Cites] Immunity. 1997 Dec;7(6):831-6 [9430228.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38361-9 [11461904.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):488-96 [11809700.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48 [12787570.001]
  • [Cites] Gan. 1980 Feb;71(1):155-6 [6966589.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Annu Rev Immunol. 2000;18:621-63 [10837071.001]
  • [Cites] J Virol. 2000 Sep;74(17):8135-9 [10933724.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4119-27 [11051265.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 30;278(3):747-52 [11095979.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):10767-74 [11278284.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2514-26 [11420661.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3164-73 [11544302.001]
  • [Cites] Oncogene. 2001 Sep 20;20(42):6073-83 [11593415.001]
  • [Cites] Pancreas. 2001 Oct;23(3):251-8 [11590320.001]
  • [Cites] Genes Dev. 1990 Nov;4(11):1875-85 [2276622.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1080-6 [1995093.001]
  • [Cites] J Immunol. 1994 Jul 15;153(2):566-73 [8021495.001]
  • [Cites] Science. 1994 Jul 22;265(5171):528-30 [7518614.001]
  • [Cites] Nature. 1994 Aug 25;370(6491):650-2 [7520535.001]
  • [Cites] Immunity. 1994 Aug;1(5):357-64 [7533644.001]
  • [Cites] Mol Cell Biol. 1995 May;15(5):2809-18 [7739562.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4243-9 [7492783.001]
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • [Cites] EMBO J. 1996 Feb 15;15(4):873-87 [8631308.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2083-90 [8628274.001]
  • [Cites] Curr Biol. 1996 Jun 1;6(6):750-2 [8793301.001]
  • [Cites] J Immunol. 1996 Nov 1;157(9):3980-7 [8892631.001]
  • [Cites] Int Immunol. 1996 Aug;8(8):1311-7 [8918700.001]
  • [Cites] Science. 1997 Apr 4;276(5309):111-3 [9082980.001]
  • [Cites] J Virol. 1997 Jun;71(6):4445-51 [9151835.001]
  • [Cites] Nature. 1997 Jul 10;388(6638):190-5 [9217161.001]
  • [Cites] AIDS. 1997 Jul;11(8):1059-61 [9223744.001]
  • [Cites] Science. 1997 Aug 8;277(5327):815-8 [9242610.001]
  • [Cites] Science. 1997 Aug 8;277(5327):818-21 [9242611.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21096-103 [9261113.001]
  • [Cites] EMBO J. 1997 Sep 1;16(17):5386-97 [9311998.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1365-72 [9334376.001]
  • [Cites] Science. 1997 Oct 31;278(5339):866-9 [9346485.001]
  • [Cites] J Virol. 1989 Aug;63(8):3220-6 [2501514.001]
  • [Cites] J Exp Med. 1990 Jul 1;172(1):121-9 [2358774.001]
  • [Cites] Annu Rev Immunol. 1998;16:225-60 [9597130.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4624-31 [9616159.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9319-24 [9689078.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5157-65 [9710600.001]
  • [Cites] J Immunol. 1998 Sep 1;161(5):2195-200 [9725211.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):2833-40 [9743343.001]
  • [Cites] Curr Opin Immunol. 1998 Oct;10(5):559-63 [9794836.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2639-47 [10072506.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2747-53 [10364001.001]
  • [Cites] Mol Cell Biol. 1999 Jul;19(7):4547-51 [10373503.001]
  • [Cites] J Immunol. 1999 Jul 15;163(2):920-6 [10395688.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] J Immunol. 1999 Aug 15;163(4):1906-13 [10438925.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Science. 1982 Aug 20;217(4561):737-9 [6980467.001]
  • [RetractionIn] J Virol. 2011 Feb;85(3):1416 [21228250.001]
  • (PMID = 15650163.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Gene Products, tax; 0 / Ligands; 0 / Membrane Glycoproteins; 0 / NF-kappa B; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC544134
  •  go-up   go-down


35. Nishiuchi T, Imachi H, Murao K, Fujiwara M, Muraoka T, Kikuchi F, Nishiuchi Y, Kushida Y, Haba R, Ishida T: Co-existence of glucagonoma with recurrent insulinoma in a patient with multiple endocrine neoplasia-type 1 (MEN-1). Endocrine; 2009 Aug;36(1):20-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-existence of glucagonoma with recurrent insulinoma in a patient with multiple endocrine neoplasia-type 1 (MEN-1).
  • Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by tumors of the parathyroid glands, the anterior pituitary, and the endocrine pancreas.
  • He was admitted to our hospital because of recurrent hypoglycemia and a growth of pancreatic tumors.
  • He subsequently underwent surgery for the pancreatic tumors.
  • The majority of these tumor cells were immunohistochemically positive for insulin and negative for glucagon.
  • A few nodules showed immunohistochemical staining positivity for glucagon but they were negative for insulin.
  • Although it is uncommon for patients with MEN1 to exhibit insulinoma and glucagonoma, this case suggests the need for careful analysis of pancreatic tumors in patients with MEN1.
  • [MeSH-major] Glucagonoma / pathology. Insulinoma / pathology. Multiple Endocrine Neoplasia Type 1 / pathology. Pancreatic Neoplasms / pathology


36. Patel M, Fine DR: Fibrogenesis in the pancreas after acinar cell injury. Scand J Surg; 2005;94(2):108-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrogenesis in the pancreas after acinar cell injury.
  • Fibrosis within the pancreas is a key feature of chronic pancreatitis and pancreatic cancer.
  • It has now been well demonstrated that following injury to acinar cells, pancreatic stellate cell activation, migration and proliferation is the key mediator of this process.
  • The pancreatic stellate cell is likely to play an important role in maintaining the normal extracellular matrix; we speculate that the dysregulation of this process is an important factor in chronic pancreatitis.
  • [MeSH-major] Pancreas / cytology. Pancreas / pathology
  • [MeSH-minor] Apoptosis / physiology. Apoptosis Regulatory Proteins. Chronic Disease. Fibrosis. Humans. Membrane Glycoproteins / metabolism. Metalloproteases / physiology. Pancreatitis / physiopathology. TNF-Related Apoptosis-Inducing Ligand. Transforming Growth Factor beta / physiology. Tumor Necrosis Factor-alpha / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16111091.001).
  • [ISSN] 1457-4969
  • [Journal-full-title] Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
  • [ISO-abbreviation] Scand J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Membrane Glycoproteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Transforming Growth Factor beta; 0 / Tumor Necrosis Factor-alpha; EC 3.4.- / Metalloproteases
  • [Number-of-references] 22
  •  go-up   go-down


37. Santini D, Poli F, Lega S: Solid-papillary tumors of the pancreas: histopathology. JOP; 2006;7(1):131-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-papillary tumors of the pancreas: histopathology.
  • A solid-pseudopapillary tumor is an uncommon and "enigmatic" pancreatic neoplasm, and the term encompasses the two most conspicuous histological features: solid and pseudopapillary areas.
  • Histologically, solid-pseudopapillary tumors are generally characterized by solid areas alternating with a pseudopapillary pattern, and cystic spaces which are the results of degenerative changes occurring in the solid neoplasm.
  • Its immunohistochemical pattern is very distinctive and neoplastic cells are consistently vimentin-, CD10- and CD56-positive.
  • Some cases express focal positivity for alpha-1-antitrypsin, alpha-1-antichymotrypsin, neuron-specific enolase and synaptophysin.
  • Endocrine and pancreatic enzyme markers are absent; the origin of solid-pseudopapillary tumors has not yet been clarified.
  • Many investigators favor the theory that solid-pseudopapillary tumors originate from multipotent primordial cells while others suggest an extra-pancreatic origin from genital ridge angle-related cells.
  • Solid-pseudopapillary tumors appear as a low malignancy tumor and only a small number of cases recur or develop metastases after resection.
  • [MeSH-major] Carcinoma, Papillary / pathology. Pancreas / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Antigens, CD56 / analysis. Cell Proliferation. Humans. Immunohistochemistry. Neoplasm Invasiveness. Neprilysin / analysis. Receptors, Progesterone / analysis. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407635.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Receptors, Progesterone; 0 / Vimentin; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


38. Hernández-Espinosa D, Miñano A, Martínez C, Pérez-Ceballos E, Heras I, Fuster JL, Vicente V, Corral J: L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol; 2006 Jul;169(1):142-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the consequences of this drug on antithrombin levels, activity, conformation, and immunohistological and ultrastructural features in plasma from acute lymphoblastic leukemia patients, HepG2 cells, and plasma and livers from mice treated with this drug.
  • Moreover, l-asparaginase impaired secretion of antithrombin by HepG2 cells.
  • Similar effects were observed for alpha1-antitrypsin in plasma, cells, and livers, and intracellular aggregates of additional proteins were observed in frontal cortex and pancreas.
  • This is the first report of a conformational drug-associated effect on serpins without genetic factors involved. l-Asparaginase treatment induces severe, acquired, and transient type I deficiency of antithrombin (and alpha1-antitrypsin) with intracellular accumulation of the nascent molecule, increasing the risk of thrombosis.
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Factor Xa / drug effects. Factor Xa / metabolism. Humans. Liver / chemistry. Liver / metabolism. Male. Mice. Microscopy, Electron, Transmission. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein Conformation. alpha 1-Antitrypsin / drug effects. alpha 1-Antitrypsin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2005 Feb;90(2):238-46 [15710578.001]
  • [Cites] Cancer. 1982 Aug 1;50(3):451-6 [7046902.001]
  • [Cites] J Thromb Haemost. 2005 Sep;3(9):1985-92 [16102104.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3388-96 [10552948.001]
  • [Cites] Leuk Res. 2000 Jul;24(7):559-65 [10867129.001]
  • [Cites] J Clin Invest. 2000 Oct;106(7):873-8 [11018075.001]
  • [Cites] Genome Res. 2000 Dec;10(12):1845-64 [11116082.001]
  • [Cites] Thromb Haemost. 2001 Jul;86(1):14-22 [11487000.001]
  • [Cites] Exp Mol Pathol. 2001 Dec;71(3):241-6 [11733949.001]
  • [Cites] N Engl J Med. 2002 Jan 3;346(1):45-53 [11778003.001]
  • [Cites] Hepatology. 2002 May;35(5):1053-62 [11981755.001]
  • [Cites] Nat Rev Genet. 2002 Oct;3(10):759-68 [12360234.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2529-33 [12517808.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15116-22 [12578831.001]
  • [Cites] J Neurochem. 2003 Jun;85(5):1117-25 [12753071.001]
  • [Cites] Clin Chem. 2003 Oct;49(10):1710-1 [14500607.001]
  • [Cites] Biochem Soc Symp. 2003;(70):163-78 [14587291.001]
  • [Cites] J Lab Clin Med. 2003 Nov;142(5):298-305 [14647033.001]
  • [Cites] Electrophoresis. 2003 Dec;24(24):4282-90 [14679575.001]
  • [Cites] Thromb Res. 1983 Feb 15;29(4):437-42 [6857592.001]
  • [Cites] Blood. 1994 Jan 15;83(2):386-91 [8286739.001]
  • [Cites] Blood Coagul Fibrinolysis. 1994 Jan;5 Suppl 1:S24-36; discussion S59-64 [8186353.001]
  • [Cites] J Clin Invest. 1994 Dec;94(6):2265-74 [7989582.001]
  • [Cites] Int J Clin Lab Res. 1995;25(3):146-8 [8562977.001]
  • [Cites] Biochem J. 1997 May 15;324 ( Pt 1):1-18 [9164834.001]
  • [Cites] Lancet. 1997 Jul 12;350(9071):134-8 [9228977.001]
  • [Cites] Mutat Res. 2005 Jan 6;569(1-2):29-63 [15603751.001]
  • [Cites] J Thromb Haemost. 2004 Dec;2(12):2170-7 [15613023.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):895-9 [14685250.001]
  • [Cites] Thromb Res. 2003;111(6):321-7 [14698648.001]
  • [Cites] Curr Med Chem. 2004 Feb;11(4):491-9 [14965229.001]
  • [Cites] J Gastroenterol. 2004;39(4):391-6 [15168253.001]
  • [Cites] J Bioenerg Biomembr. 2004 Aug;36(4):303-7 [15377862.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1973;39:185-248 [4583638.001]
  • [Cites] Lancet. 1980 Mar 22;1(8169):649-50 [6102647.001]
  • [Cites] Med Pediatr Oncol. 1979;7(4):335-40 [296786.001]
  • [Cites] Curr Protein Pept Sci. 2005 Apr;6(2):197-203 [15853655.001]
  • (PMID = 16816368.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha 1-Antitrypsin; 9001-31-4 / Fibrin; EC 3.4.21.6 / Factor Xa; EC 3.5.1.1 / Asparaginase
  • [Other-IDs] NLM/ PMC1698772
  •  go-up   go-down


39. Carvalho KM, Morais TC, de Melo TS, de Castro Brito GA, de Andrade GM, Rao VS, Santos FA: The natural flavonoid quercetin ameliorates cerulein-induced acute pancreatitis in mice. Biol Pharm Bull; 2010;33(9):1534-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cerulein significantly enhanced the serum levels of amylase and lipase, and pancreatic myeloperoxidase activities, malondialdehyde and the proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6, as well as the pancreatic wet weight/body weight ratio.
  • Histological assessment of the pancreas showed tissue edema, neutrophil infiltration, acinar vacuolization, and cell necrosis and a marked increase in the immunoreactivity staining for TNF-alpha.
  • Pretreatment with quercetin or thalidomide significantly attenuated the severity of cerulein-induced acute pancreatitis as evidenced by effective reductions in the pancreatic wet weight/body weight ratio, biochemical indices, proinflammatory cytokines, myeloperoxidase activity, malondialdehyde formation, and an increase in antiinflammatory cytokine IL-10.
  • Quercetin treatment also markedly suppressed the histological changes such as pancreatic edema, inflammatory cell infiltration, acinar cell necrosis, and the expression of TNF-alpha.

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • Hazardous Substances Data Bank. QUERCETIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20823570.001).
  • [ISSN] 1347-5215
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Flavonoids; 888Y08971B / Ceruletide; 9IKM0I5T1E / Quercetin
  •  go-up   go-down


40. Hirashima K, Takamori H, Hirota M, Tanaka H, Ichihara A, Sakamoto Y, Ikuta Y, Karashima R, Watanabe M, Iyama K, Baba H: Multiple gastrointestinal stromal tumors in neurofibromatosis type 1: report of a case. Surg Today; 2009;39(11):979-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple gastrointestinal stromal tumors in neurofibromatosis type 1: report of a case.
  • This report presents a case of multiple gastrointestinal stromal tumors (GIST) with neurofibromatosis type 1 (NF1).
  • A 68-year-old woman was admitted to the hospital because of a tumor close to the head of the pancreas.
  • Imaging studies revealed submucosal tumors of the duodenum.
  • The retroperitoneal tumor was diagnosed before surgery.
  • Besides the main tumor in the duodenum, multiple small submucosal tumors were found in the duodenum and upper part of the jejunum during the operation.
  • All of these tumors were resected.
  • The histological diagnosis of all these tumors was GISTs.
  • These tumors were immunohistochemically positive for KIT, but they demonstrated no mutation in c-kit exons 9, 11, 13, and 17, and platelet-derived growth factor receptor alpha exons 12 and 18.
  • [MeSH-major] Digestive System Surgical Procedures / methods. Duodenum / pathology. Gastrointestinal Stromal Tumors / complications. Jejunum / pathology. Neurofibromatosis 1 / complications
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans


41. Stone SP, Buescher LS: Life-threatening paraneoplastic cutaneous syndromes. Clin Dermatol; 2005 May-Jun;23(3):301-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Life-threatening paraneoplastic cutaneous syndromes.
  • Paraneoplastic syndromes are diseases or symptom complexes associated with malignancy, usually internal.
  • In this article, we discuss the link between malignancy and such dermatologic disorders as acanthosis nigricans, acrokeratosis paraneoplastica of Bazex, dermatomyositis, erythema gyratum repens, necrolytic migratory erythema (glucagonoma syndrome), and paraneoplastic pemphigus and discuss, where such information is known, the mechanism by which these paraneoplastic diseases occur.
  • [MeSH-major] Paraneoplastic Syndromes / diagnosis. Skin Diseases / diagnosis
  • [MeSH-minor] Critical Illness. Erythema / diagnosis. Humans. Neoplasms / diagnosis. Pemphigus / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896545.001).
  • [ISSN] 0738-081X
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


42. Ferrand A, Vatinel S, Kowalski-Chauvel A, Bertrand C, Escrieut C, Fourmy D, Dufresne M, Seva C: Mechanism for Src activation by the CCK2 receptor: Patho-physiological functions of this receptor in pancreas. World J Gastroenterol; 2006 Jul 28;12(28):4498-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanism for Src activation by the CCK2 receptor: Patho-physiological functions of this receptor in pancreas.
  • AIM: To investigate in vivo, whether CCK2 receptors (CCK2R) regulate proteins known to play a crucial role in cell proliferation and cancer development and analyse in vitro the molecular mechanisms that lead to Src activation; in particular, to identify the domains within the CCK2R sequence that are implicated in this activation.
  • We used pancreatic tissues derived from wild type or Elas-CCK2 mice that expressed the CCK2R in pancreatic acini, displayed an increased pancreatic growth and developed preneoplastic lesions.
  • The pancreatic tumor cell line AR4-2J expressing the endogenous CCK2R or COS-7 cells transiently transfected with wild type or mutant CCK2R were used as in vitro models to study the mechanism of Src activation.
  • Src activation was measured by in vitro kinase assays, ERK activation by western blot using anti-phospho-ERK antibodies and the involvement of Src in gastrin-induced cell proliferation by MTT test.
  • RESULTS: We showed in vivo that the targeted CCK2R expression in the pancreas of Elas-CCK2 mice, led to the activation of Src and the ERK pathway.
  • Src was activated upstream of the ERK pathway by the CCK2R in pancreatic tumoral cells and contributed to the proliferative effects mediated by this receptor.
  • CONCLUSION: Deregulation of the Src/ERK pathway by the CCK2R might represent an early step that contributes to cell proliferation, formation of preneoplastic lesions and pancreatic tumor development.
  • [MeSH-major] Pancreas / metabolism. Pancreatic Neoplasms / physiopathology. Precancerous Conditions / physiopathology. Receptor, Cholecystokinin B / physiology. src-Family Kinases / metabolism
  • [MeSH-minor] Amino Acid Motifs / physiology. Animals. Cell Line. Cell Proliferation. Cell Transformation, Neoplastic. Enzyme Activation / physiology. Extracellular Signal-Regulated MAP Kinases / metabolism. GTP-Binding Protein alpha Subunits, Gq-G11 / physiology. Gene Expression Regulation. Gene Expression Regulation, Neoplastic. Mice. Mice, Transgenic. Protein Structure, Tertiary / physiology. Signal Transduction / physiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17321-7 [10748160.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2770-7 [15805277.001]
  • [Cites] J Biol Chem. 2000 Dec 8;275(49):38131-4 [11013230.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13240-7 [11278940.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):428-37 [11832457.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48755-63 [12239223.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2016-9 [12727811.001]
  • [Cites] J Biol Chem. 2004 Feb 27;279(9):8212-8 [14670955.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jun;286(6):G992-9 [14764442.001]
  • [Cites] FEBS Lett. 2004 Jun 18;568(1-3):89-93 [15196926.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 6;1704(1):1-10 [15238241.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5829-33 [2393852.001]
  • [Cites] FEBS Lett. 1996 Jan 2;378(1):74-8 [8549807.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1254-62 [9797382.001]
  • [Cites] Gastroenterology. 1999 Jan;116(1):78-89 [9869605.001]
  • [Cites] FEBS Lett. 1999 Feb 26;445(2-3):251-5 [10094466.001]
  • [Cites] J Biol Chem. 1999 Jul 16;274(29):20657-63 [10400698.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):8028-36 [15585638.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10710-5 [15640156.001]
  • [Cites] Cancer Control. 2000 Sep-Oct;7(5):421-7 [11000611.001]
  • (PMID = 16874861.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptor, Cholecystokinin B; EC 2.7.10.2 / src-Family Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gq-G11
  • [Other-IDs] NLM/ PMC4125636
  •  go-up   go-down


43. Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, Bardeesy N, Sun H, Williams N, Minna JD, Brekken RA: Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res; 2010 Apr 1;70(7):2852-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.
  • Failure of chemotherapy in the treatment of pancreatic cancer is often due to resistance to therapy-induced apoptosis.
  • We show that JP1201, a Smac mimetic, is a potent enhancer of chemotherapy in robust mouse models of pancreatic cancer.
  • Combination of JP1201 with gemcitabine reduced primary and metastatic tumor burden in orthotopic xenograft and syngenic tumor models, induced regression of established tumors, and prolonged survival in xenograft and transgenic models of pancreatic cancer.
  • The effect of JP1201 was phenocopied by XIAP small interfering RNA in vitro and correlated with elevated levels of tumor necrosis factor alpha protein in vivo.
  • The continued development of JP1201 and other strategies designed to enhance therapy-induced apoptosis in pancreatic cancer is warranted.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):17-22 [12559172.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7806-19 [15314185.001]
  • [Cites] Science. 2004 Sep 3;305(5689):1471-4 [15353805.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):876-85 [16239906.001]
  • [Cites] Pancreas. 2006 Apr;32(3):288-96 [16628085.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3265-73 [17094439.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):957-66 [17339366.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2344-52 [17311258.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):445-56 [17996648.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):737-47 [17846863.001]
  • [Cites] Cell. 2007 Nov 16;131(4):669-81 [18022362.001]
  • [Cites] Cell. 2007 Nov 16;131(4):682-93 [18022363.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11493-8 [18089776.001]
  • [Cites] Cell. 2008 May 16;133(4):693-703 [18485876.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4340-6 [18519694.001]
  • [Cites] Mol Cancer. 2008;7:64 [18652674.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7956-65 [18829553.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9384-93 [19010913.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2425-34 [19258513.001]
  • [Cites] Mol Cancer Ther. 2009 Jun;8(6):1636-45 [19509265.001]
  • [Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]
  • [Cites] Cell. 2009 Jun 12;137(6):1100-11 [19524512.001]
  • [Cites] Neoplasia. 2009 Aug;11(8):743-52 [19649204.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):401-10 [12042762.001]
  • [Cites] Nat Med. 2002 Aug;8(8):808-15 [12118245.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:6 [12605713.001]
  • (PMID = 20332237.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA070907-12; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / P50 CA070907-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / RNA, Small Interfering; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / Tumor Necrosis Factor-alpha; 0 / X-Linked Inhibitor of Apoptosis Protein; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ NIHMS175711; NLM/ PMC2848888
  •  go-up   go-down


44. Cheshire H, Stather P, Vorster J: Acquired acrodermatitis enteropathica due to zinc deficiency in a patient with pre-existing Darier's disease. J Dermatol Case Rep; 2009 Nov 28;3(3):41-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired acrodermatitis enteropathica due to zinc deficiency in a patient with pre-existing Darier's disease.
  • Typically these patches start near the body's orifices before migrating to other sites, however in this patient the presentation was atypical thus delaying the diagnosis.
  • OBSERVATIONS: We report a case of an atypical presentation of acrodermatitis enteropathica (AE) due to acquired zinc deficiency in a 65 year old female patient with a previous diagnosis of histologically confirmed Darier's disease.
  • Acrodermatitis enteropathica typically presents in infants, either due to an autosomal recessive genetic disorder, or after the cessation of breast feeding.
  • In adults acquired zinc deficiency can be caused by glucagonoma syndrome, poor nutritional state, intestinal malabsorption, nephrotic syndrome and after major trauma (i.e. burns or significant surgery).
  • In our patient low zinc levels confirmed hypozincaemia and the diagnosis of acrodermatitis enteropathica.
  • CONCLUSION: We believe this to be an unusual presentation of acrodermatitis enteropathica due to a probable dietary zinc deficiency in a lady with pre-existing Darier's disease which may possibly have influenced the uncharacteristic clinical presentation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Dermatol. 2000 Nov-Dec;18(6):745-8 [11173209.001]
  • [Cites] Br J Dermatol. 1979 Nov;101(5):573-9 [117822.001]
  • [Cites] Int J Dermatol. 2005 Mar;44(3):184-92 [15807723.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):116-24 [17190629.001]
  • [Cites] Hum Mutat. 2009 Jun;30(6):926-33 [19370757.001]
  • [Cites] Exp Gerontol. 2008 May;43(5):394-408 [18221847.001]
  • [Cites] J Trace Elem Med Biol. 2009;23(3):183-94 [19486828.001]
  • [Cites] Curr Opin Gastroenterol. 2009 Mar;25(2):136-43 [19528881.001]
  • [Cites] Biol Trace Elem Res. 1995 Aug-Sep;49(2-3):211-25 [8562288.001]
  • [Cites] Arch Toxicol. 2006 Jan;80(1):1-9 [16187101.001]
  • [Cites] J Trace Elem Med Biol. 2006;20(1):3-18 [16632171.001]
  • [Cites] Br J Dermatol. 2009 Jul;161(1):184-6 [19416256.001]
  • (PMID = 21886729.001).
  • [ISSN] 1898-7249
  • [Journal-full-title] Journal of dermatological case reports
  • [ISO-abbreviation] J Dermatol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3157796
  • [Keywords] NOTNLM ; Darier's disease / acrodermatitis enteropathica / hair loss / mucous membranes / zinc
  •  go-up   go-down


45. Lewis RB, Lattin GE Jr, Paal E: Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics; 2010 Oct;30(6):1445-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors: radiologic-clinicopathologic correlation.
  • Pancreatic endocrine tumors (PETs) are primarily well-differentiated tumors composed of cells that resemble normal islet cells but that arise from pancreatic ductal cells.
  • They are classified as functioning or nonfunctioning according to their associated clinical symptoms; insulinoma, gastrinoma, and glucagonoma are the most common functioning PETs.
  • Most are sporadic, but some are associated with familial syndromes such as multiple endocrine neoplasia type 1, von Hippel-Lindau syndrome, and neurofibromatosis type 1.
  • At imaging, PETs typically appear as well-defined hypervascular masses, a finding indicative of their rich capillary network.
  • Cystic change, calcification, and necrosis are common in large tumors, which are associated with a poorer prognosis and a higher prevalence of local and vascular invasion and metastases than are smaller tumors.
  • Poorly differentiated PETs are rare and have an infiltrative appearance; patients with such tumors have a poor prognosis.
  • Knowledge of the characteristic clinical, pathologic, and radiologic features of PETs is important in the evaluation and management of patients with a suspected clinical syndrome or a pancreatic mass.
  • [MeSH-major] Diagnostic Imaging. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / epidemiology. Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / epidemiology. Carcinoma, Islet Cell / pathology. Diagnosis, Differential. Humans. Multiple Endocrine Neoplasia Type 1 / pathology. Neurofibromatosis 1 / pathology. Prevalence. von Hippel-Lindau Disease / pathology

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © RSNA, 2010.
  • (PMID = 21071369.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


46. Jeong DH, Kim HK, Prince AE, Lee DS, Kim YN, Han J, Kim KT: Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix. J Gynecol Oncol; 2008 Sep;19(3):173-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix.
  • OBJECTIVE: To compare plasma protein expression between patients with squamous cell carcinoma (SCC) of the cervix and normal controls.
  • METHODS: Plasma samples from patients with benign gynecological disease (normal cervix, n=6) and cervical cancer (SCC, n=6) were subjected to plasma proteomic analysis using two dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization mass spectroscopy (MALDI-MS).
  • Western blotting and immunoturbidimetric assay were performed to validate the results of 2-DE.
  • RESULTS: Eight proteins showed differential expression between controls and SCC patients; six (ceruloplasmin, complement C3, afamin precursor, alpha-1-B-glycoprotein, transferrin, alpha-fibrinogen precursor) were up-regulated, while two (chain A, crystal structure of antithrombin and apolipoprotein A-IV precursor) were down-regulated in the plasma of SCC patients.
  • Western blotting analysis revealed significant elevation of ceruloplasmin, complement C3, afamin, and alpha-1-B-glycoprotein in the plasma of SCC patients in comparison to controls.
  • Immunoturbidimetric assay of a larger group confirmed the results of 2-DE and Western blotting, and showed that ceruloplasmin and complement C3 were significantly elevated in the plasma of SCC patients in comparison with controls and patients with carcinoma in situ (CIS) of the uterine cervix.
  • CONCLUSION: Plasma protein expression determined using 2-DE and MALDI-MS will give a chance to identify tumor-specific biomarkers for SCC of the cervix.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1992 May;140(5):1039-43 [1374587.001]
  • [Cites] Anal Biochem. 1992 May 15;203(1):173-9 [1524213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2363-7 [3458201.001]
  • [Cites] J Trace Elem Med Biol. 2004;18(1):1-8 [15487757.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]
  • [Cites] Biosci Biotechnol Biochem. 2003 Jul;67(7):1574-7 [12913303.001]
  • [Cites] Immunol Rev. 2001 Apr;180:35-48 [11414361.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1B):629-32 [11299817.001]
  • [Cites] Cancer Lett. 2000 Nov 28;160(2):229-36 [11053653.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1108-21 [10699902.001]
  • [Cites] Mol Immunol. 1999 Sep-Oct;36(13-14):929-39 [10698347.001]
  • [Cites] Pancreas. 2008 Jan;36(1):61-9 [18192883.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7370-9 [18094419.001]
  • [Cites] Electrophoresis. 2007 Jun;28(12):1989-96 [17503403.001]
  • [Cites] Clin Chim Acta. 2007 Feb;377(1-2):119-26 [17067565.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):299-310 [16924372.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1216-24 [16803509.001]
  • [Cites] Proteomics. 2006 May;6(9):2865-73 [16586433.001]
  • [Cites] J Med Invest. 2006 Feb;53(1-2):20-8 [16537992.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4581-8 [16240287.001]
  • [Cites] Proteomics. 2005 Oct;5(15):4034-45 [16152657.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1073-85 [16083256.001]
  • [Cites] Adv Clin Chem. 2005;39:159-84 [16013671.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):889-99 [15952736.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4613-9 [15741220.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):895-905 [15726105.001]
  • [Cites] Immunopharmacology. 1999 May;42(1-3):39-45 [10408364.001]
  • [Cites] Int Urol Nephrol. 1997;29(4):427-32 [9405999.001]
  • [Cites] Biotechnology (N Y). 1996 Jan;14(1):61-5 [9636313.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1329-35 [8958307.001]
  • [Cites] Gut. 1996 Feb;38(2):248-53 [8801206.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):129-42 [8686736.001]
  • [Cites] JAMA. 1994 Jun 15;271(23):1866-9 [8196145.001]
  • [Cites] J Biol Chem. 1994 Jul 8;269(27):18149-54 [7517938.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2808-17 [7514955.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):5481-4 [7509788.001]
  • [Cites] Anticancer Res. 1994 Sep-Oct;14(5B):2201-3 [7840524.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1406-12 [8381706.001]
  • (PMID = 19471570.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676467
  • [Keywords] NOTNLM ; MALDI-MS / Plasma proteins / Squamous cell carcinoma / Two dimensional gel electrophoresis / Uterine cervical cancer
  •  go-up   go-down


47. Chamson-Reig A, Arany EJ, Summers K, Hill DJ: A low protein diet in early life delays the onset of diabetes in the non-obese diabetic mouse. J Endocrinol; 2009 May;201(2):231-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dietary insult in early life can affect the development and future function of the endocrine pancreas.
  • Serum insulin and pancreatic insulin content were reduced in LP-fed NOD offspring at 8 weeks, as were serum interferon gamma and pancreatic tumor necrosis factor alpha, while the number of pancreatic islets demonstrating peri-insulitis, and the degree of invasiveness were reduced.
  • To determine if LP caused early morphometric changes in the pancreas, we measured mean islet area at days 3 and 21.
  • Mean islet size did not differ with diet, but by 8 weeks of age LP-fed NOD females exhibited a significantly reduced islet number and mean islet area, and a lower fractional area of pancreas occupied by both alpha- and beta-cells than control-fed mice.
  • The mechanism is likely to involve both altered beta-cell morphology and function and changes in cytotoxic cytokines.

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19228796.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin
  •  go-up   go-down


48. Wang F, Li SS, Segersvärd R, Strömmer L, Sundqvist KG, Holgersson J, Permert J: Hypoxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energy homeostasis. Am J Pathol; 2007 Feb;170(2):469-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energy homeostasis.
  • Intratumoral hypoxia and paracrine insulin stimulate the expression of hypoxia inducible factor-1alpha (HIF-1alpha) in pancreatic cancer cells.
  • In the present studies, we investigated whether insulin-induced HIF-1alpha expression is a prerequisite for insulin to induce other trophic effects in MiaPaCa2 human pancreatic cancer cells and whether inhibition of HIF-1alpha expression would decrease tumor glycolysis and improve host energy homeostasis.
  • We found that hypoxia was a prerequisite for induction of HIF-1alpha mRNA expression by insulin in MiaPaCa2 cells.
  • Under hypoxic conditions, insulin stimulated glycolysis, cell proliferation, and the secretion of vascular endothelial growth factor in regular MiaPaCa2 cells but not in a MiaPaCa2 variant (si-MiaPaCa2) that expressed specific short interfering RNA for HIF-1alpha and therefore lacked HIF-1alpha protein.
  • When si-MiaPaCa2 cells were transplanted into the pancreas of athymic mice, they were less tumorigenic and expressed less hexokinase than regular MiaPaCa2 cells.
  • Body weight gain was attenuated in mice hosting tumors composed of regular MiaPaCa2 but not si-MiaPaCa2 cells.
  • These results suggest that an interaction between insulin and HIF-1alpha helps sustain pancreatic cancer cells and disturbs host energy homeostasis.
  • [MeSH-major] Glycolysis / drug effects. Homeostasis / drug effects. Hypoglycemic Agents / pharmacology. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Insulin / pharmacology. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Hypoxia. Cell Line, Tumor. Cell Proliferation / drug effects. Gene Expression Regulation / drug effects. Hexokinase / biosynthesis. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2005 Jan 6;569(1-2):87-100 [15603754.001]
  • [Cites] Cell Res. 2006 Jun;16(6):548-58 [16775626.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4694-700 [16000563.001]
  • [Cites] Hum Mol Genet. 2005 Aug 1;14(15):2231-9 [15987702.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1541-5 [10749120.001]
  • [Cites] Pancreas. 2000 Oct;21(3):310-20 [11039477.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):919-22 [11072146.001]
  • [Cites] Cell Growth Differ. 2001 Jul;12(7):363-9 [11457733.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6548-54 [11522653.001]
  • [Cites] EMBO J. 2001 Sep 17;20(18):5197-206 [11566883.001]
  • [Cites] J Clin Invest. 2002 Mar;109(6):805-15 [11901189.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):480-2 [11920604.001]
  • [Cites] Am J Epidemiol. 2002 May 1;155(9):783-92 [11978580.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27975-81 [12032158.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38205-11 [12149254.001]
  • [Cites] Blood. 2003 Feb 1;101(3):907-14 [12393531.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1001-11 [12937141.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4721-7 [14981919.001]
  • [Cites] Exp Mol Med. 2004 Feb 29;36(1):1-12 [15031665.001]
  • [Cites] Gut. 1976 Sep;17(9):685-91 [976808.001]
  • [Cites] Pathol Res Pract. 1986 Mar;181(1):77-84 [3517840.001]
  • [Cites] Diabet Med. 1985 Mar;2(2):113-6 [2952394.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2284-303 [3326653.001]
  • [Cites] Eur J Surg. 1993 Feb;159(2):101-7 [8098623.001]
  • [Cites] Diabetologia. 1995 Mar;38(3):262-8 [7758870.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] J Biol Chem. 1996 Jul 26;271(30):17771-8 [8663540.001]
  • [Cites] Nat Biotechnol. 1997 Sep;15(9):871-5 [9306402.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):5085-94 [9724644.001]
  • [Cites] J Surg Res. 1998 Sep;79(1):13-9 [9735234.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3915-8 [10463582.001]
  • [Cites] Am J Surg. 2006 Feb;191(2):191-7 [16442944.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):417-25 [15967119.001]
  • (PMID = 17255315.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoglycemic Agents; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Insulin; 0 / Vascular Endothelial Growth Factor A; EC 2.7.1.1 / Hexokinase
  • [Other-IDs] NLM/ PMC1851851
  •  go-up   go-down


49. Shimizu K, Kobayashi M, Tahara J, Shiratori K: Cytokines and peroxisome proliferator-activated receptor gamma ligand regulate phagocytosis by pancreatic stellate cells. Gastroenterology; 2005 Jun;128(7):2105-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokines and peroxisome proliferator-activated receptor gamma ligand regulate phagocytosis by pancreatic stellate cells.
  • BACKGROUND & AIMS: Pancreatic stellate cells have been characterized as the major source of extracellular matrix and cytokine production in the pancreas.
  • This study showed that pancreatic stellate cells have a phagocytic function.
  • METHODS: The morphological features of periacinar phagocytic cells were investigated by immunohistochemically staining serial sections of the pancreas from male WBN/Kob rats and an animal model of acute pancreatitis for glial fibrillary acidic protein and alpha-smooth muscle actin.
  • Pancreatic stellate cells were assayed for phagocytic activity by incubating them with senescent polymorphonuclear neutrophils or fluorescence-labeled latex beads in the presence or absence of cytokines, growth factors, and peroxisome proliferator-activated receptor gamma ligand.
  • RESULTS: Phagocytic cells were observed in areas of inflammation, and they were identical to the glial fibrillary acidic protein-positive and alpha-smooth muscle actin-positive cells, thus suggesting that they were pancreatic stellate cells.
  • Aged polymorphonuclear neutrophils were ingested into the cytoplasm of the pancreatic stellate cells.
  • Transforming growth factor beta, tumor necrosis factor alpha, and interleukin 1beta decreased the phagocytic activity of pancreatic stellate cells, whereas troglitazone induced a dose-dependent increase in both phagocytic activity and expression of CD36.
  • CONCLUSIONS: Pancreatic stellate cells act as resident phagocytic cells, and CD36 promotes troglitazone-induced phagocytic activity via peroxisome proliferator-activated receptor gamma transactivation.
  • Because phagocytosis is essential to limit the extent of inflammation, enhancement of phagocytic activity may provide an important approach to the treatment of pancreatic diseases.
  • [MeSH-major] PPAR gamma / physiology. Pancreas / cytology. Phagocytosis / physiology
  • [MeSH-minor] Animals. Antigens, CD36 / physiology. Cell Culture Techniques. Immunohistochemistry. Inflammation. Ligands. Male. Pancreatic Diseases / therapy. Rats

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Gastroenterology. 2005 Aug;129(2):775
  • (PMID = 15940641.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD36; 0 / Ligands; 0 / PPAR gamma
  •  go-up   go-down


50. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ: CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia; 2006 May;8(5):394-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiogenesis is one of the critical steps in tumor growth and metastasis.
  • The goal of this study was to evaluate whether the antitumor activity of CCI-779 is related to antiangiogenic effects in vivo in tumors of mice bearing human rhabdomyosarcoma (RMS) xenografts.
  • Based on these data, an intermittent treatment schedule (every 3 days for 30 days) was chosen and displayed a significant suppression of both tumor growth and mTOR signaling.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2803-7 [10914727.001]
  • [Cites] Oncologist. 1999;4(1):34-44 [10337369.001]
  • [Cites] Cell. 2001 May 4;105(3):345-55 [11348591.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1758-64 [11410517.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5731-5 [11479208.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10320-5 [11504907.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2406-11 [15781656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):273-9 [11981271.001]
  • [Cites] Curr Opin Investig Drugs. 2002 Feb;3(2):295-304 [12020063.001]
  • [Cites] FASEB J. 2002 Jun;16(8):771-80 [12039858.001]
  • [Cites] Pancreas. 2002 Aug;25(2):122-9 [12142733.001]
  • [Cites] Neoplasia. 2002 Sep-Oct;4(5):400-8 [12192598.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):505-15 [10688871.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):337-44 [10888419.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):648-57 [12172553.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):727-39 [12360276.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3767-75 [12393646.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):559-65 [12766775.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):566-71 [12766776.001]
  • [Cites] Cancer Biol Ther. 2003 May-Jun;2(3):222-32 [12878853.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Nat Rev Drug Discov. 2003 Oct;2(10):803-11 [14526383.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8205-11 [14603261.001]
  • [Cites] Trends Biochem Sci. 2003 Nov;28(11):573-6 [14607085.001]
  • [Cites] Trends Biochem Sci. 2004 Jan;29(1):32-8 [14729330.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2336-47 [15136596.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6993-7000 [15501979.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1227-36 [1377606.001]
  • [Cites] Med Res Rev. 1994 Jan;14(1):1-22 [8309312.001]
  • [Cites] Cell. 1994 Oct 21;79(2):185-8 [7525076.001]
  • [Cites] Semin Pediatr Surg. 1994 Aug;3(3):203-6 [7987636.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Cell Growth Differ. 1995 Mar;6(3):263-9 [7794794.001]
  • [Cites] Nature. 1995 Oct 5;377(6548):441-6 [7566123.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Cell. 1996 Aug 23;86(4):517-20 [8752206.001]
  • [Cites] Curr Opin Oncol. 1996 Jul;8(4):311-6 [8869806.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8104-9 [9223322.001]
  • [Cites] Med Pediatr Oncol. 1998 May;30(5):269-75 [9544222.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1527-32 [11245461.001]
  • (PMID = 16790088.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Vascular Endothelial Growth Factor A; 624KN6GM2T / temsirolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1592447
  •  go-up   go-down


56. Shen SG, Zhang D, Hu HT, Li JH, Wang Z, Ma QY: Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro. World J Gastroenterol; 2008 Apr 21;14(15):2358-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro.
  • AIM: To discuss the expression of alpha-adrenoreceptors in pancreatic cancer cell lines PC-2 and PC-3 and the effects of alpha1- and alpha2-adrenoreceptor antagonists, yohimbine and urapidil hydrochloride, on the cell lines in vitro.
  • METHODS: We cultured the human ductal pancreatic adenocarcinoma cell lines PC-2 and PC-3 and analyzed the mRNA expression of alpha1- and alpha2-adrenergic receptors by reverse transcription polymerase chain reaction (RT-PCR).
  • The effects of yohimbine and urapidil hydrochloride on cell proliferation were assessed by 3-(4,5-dimethylthiasol-2-yl)-2,4,-diphenyltetrazolium bromide (MTT) assay.
  • MTT assays showed that urapidil hydrochloride had no effect on PC-3 cell lines.
  • However, exposure to urapidil hydrochloride increased DNA synthesis in PC-2 cell lines as compared to the control group.
  • PC-2 cell lines were sensitive to both drugs.
  • The proliferation of the 2 cell lines was inhibited by yohimbine.
  • Cell proliferation was inhibited by yohimbine via apoptosis induction.
  • CONCLUSION: The expression of alpha1- and alpha2-adrenoreceptors is different in PC-2 and PC-3 cell lines, which might be indicative of their different functions.
  • The alpha2-adrenoceptor antagonist, yohimbine, can inhibit the proliferation of both cell lines and induce their apoptosis, suggesting that yohimbine can be used as an anticancer drug for apoptosis of PC-2 and PC-3 cells.
  • [MeSH-major] Adrenergic alpha-2 Receptor Antagonists. Adrenergic alpha-Antagonists / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Cell Proliferation / drug effects. Pancreatic Neoplasms / pathology. Yohimbine / pharmacology
  • [MeSH-minor] Adrenergic alpha-1 Receptor Antagonists. Cell Line, Tumor. DNA Replication / drug effects. Dose-Response Relationship, Drug. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. In Situ Nick-End Labeling. Piperazines / pharmacology. RNA, Messenger / metabolism. Receptors, Adrenergic, alpha-1 / metabolism. Receptors, Adrenergic, alpha-2 / genetics. Receptors, Adrenergic, alpha-2 / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):50-61 [16292538.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):197-209 [16549324.001]
  • [Cites] Ann Oncol. 2007 Jun;18 Suppl 7:vii1-vii10 [17600091.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Sep;4(9):526-35 [17728711.001]
  • [Cites] Pancreatology. 2007;7(5-6):459-69 [17912010.001]
  • [Cites] Circulation. 2000 Feb 15;101(6):689-94 [10673263.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4550-5 [10969806.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):473-9 [11238189.001]
  • [Cites] Pharmacol Res. 2001 Sep;44(3):195-208 [11529686.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):482-9 [11819814.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):455-63 [12189387.001]
  • [Cites] Herz. 2002 Nov;27(7):683-90 [12439640.001]
  • [Cites] J Urol. 2003 Apr;169(4):1520-5 [12629407.001]
  • [Cites] Biochem Pharmacol. 2003 May 1;65(9):1489-94 [12732361.001]
  • [Cites] Vet Res Commun. 2003 Sep;27 Suppl 1:415-8 [14535443.001]
  • [Cites] Am J Cardiol. 1987 May 29;59(14):18G-28G [2884849.001]
  • [Cites] J Biol Chem. 1993 Oct 25;268(30):22235-8 [8226727.001]
  • [Cites] Pharmacol Res. 1996 Apr-May;33(4-5):255-60 [8938018.001]
  • [Cites] J Auton Pharmacol. 1997 Dec;17(6):331-43 [9610428.001]
  • [Cites] Eur J Pharmacol. 1998 Nov 13;361(1):1-15 [9851536.001]
  • [Cites] Eur Urol. 1999;36 Suppl 1:80-8 [10393479.001]
  • [Cites] Breast Cancer Res Treat. 1999 May;55(1):41-9 [10472778.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4510-5 [10493497.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):231-41 [16725343.001]
  • (PMID = 18416462.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-2 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Antineoplastic Agents; 0 / Piperazines; 0 / RNA, Messenger; 0 / Receptors, Adrenergic, alpha-1; 0 / Receptors, Adrenergic, alpha-2; 2Y49VWD90Q / Yohimbine; A78GF17HJS / urapidil
  • [Other-IDs] NLM/ PMC2705090
  •  go-up   go-down


57. Li Q, Feng FY, Chen Q, Jiao SC, Li F, Wang HQ, Huang WX, Ling CQ, Li MZ, Ren J, Zhang Y, Qin FZ, Zhou MZ, Zhu RZ: [Multicenter phase II clinical trial of uroacitides injection in the treatment for advanced malignant tumors]. Zhonghua Zhong Liu Za Zhi; 2008 Jul;30(7):534-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multicenter phase II clinical trial of uroacitides injection in the treatment for advanced malignant tumors].
  • OBJECTIVE: To investigate the efficacy, safety and the life quality improvement of uroacitides injection in the treatment for patients with advanced malignant tumors.
  • METHODS: A total of 160 patients with advanced stage cancers were enrolled into this multicenter, open and non-randomized phase II clinical trial, including cancers of the lung (33 cases), liver (45 cases), breast (17 cases), esophagus (11 cases), stomach (18 cases), colon (19 cases), pancreas (3 cases) and kidney (4 cases), and glioma (10 cases).
  • The total objective response rate (ORR, CR + PR)) and tumor control rate (CR + PR + MR + SD) of the 138 evaluable patients were 5.8% and 65.2%, respectively.
  • [MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Catheterization, Central Venous. Colorectal Neoplasms / blood. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Humans. Nausea / chemically induced. Neoplasm Staging. Quality of Life. Remission Induction. Salvage Therapy. Treatment Outcome. Vomiting / chemically induced. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062723.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Peptides; 0 / Phenylacetates; 0 / alpha-Fetoproteins; 0 / cell differentiation agent II; EC 2.1.1.- / Methyltransferases
  •  go-up   go-down


58. Dourakis SP, Alexopoulou A, Georgousi KK, Delladetsima JK, Tolis G, Archimandritis AJ: Glucagonoma syndrome: survival 21 years with concurrent liver metastases. Am J Med Sci; 2007 Sep;334(3):225-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucagonoma syndrome: survival 21 years with concurrent liver metastases.
  • A patient who survived for 21 years since initial discovery of glucagonoma with concurrent liver metastases is described.
  • Psychiatric symptoms, weight loss, necrolytic migratory erythema, diarrhea, and diabetes mellitus developed gradually after diagnosis of the tumor.
  • The longevity of this patient may be related to the slow tumor growth expressed histologically by ischemic necrosis of the malignant cells and in imaging by extensive tumor calcifications, a very rare finding in this type of the tumor.
  • [MeSH-major] Glucagonoma / pathology. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology


59. Vervoort L, Burvenich I, Staelens S, Dumolyn C, Waegemans E, Van Steenkiste M, Baird SK, Scott AM, De Vos F: Preclinical evaluation of monoclonal antibody 14C5 for targeting pancreatic cancer. Cancer Biother Radiopharm; 2010 Apr;25(2):193-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of monoclonal antibody 14C5 for targeting pancreatic cancer.
  • The use of radiolabeled antibodies that are able to target primary tumors as well as metastatic tumor sites with minimal reactivity to normal tissues is a promising approach for treating pancreatic cancer.
  • In this study, the integrin alpha(v)beta(5) is studied as a target for the diagnosis of and potential therapy for human pancreatic cancer by using the radiolabeled murine monoclonal antibody (mAb) 14C5.
  • Biopsy specimens from human pancreatic tumors were examined for the expression of the integrin alpha(v)beta(5).
  • The pancreatic tumor cell line Capan-1 was used to test the in vitro targeting potency of mAb 14C5 labeled with 125/131-iodine and 111-indium.
  • Biodistribution and tumor-targeting characteristics were studied in Capan-1 xenografts.
  • All tumor sections were positive for the integrin alpha(v)beta(5), with an extensive positive staining of the stroma.
  • In vivo radioisotope tumor uptake was maximum at 48-72 hours, with the uptake of (111)In-p-SCN-Bz-DOTA-14C5 (35.84 +/- 8.64 percentage of injected dose per g [%ID/g]) being 3.9- and 2.2-folds higher than (131)I-14C5 (12.16 +/- 1.03%ID/g) and (111)In-p-SCN-Bz-DTPA-14C5 (14.30 +/- 3.76%ID/g), respectively.
  • Planar gamma imaging with mAb 14C5 indicated clear localization of the pancreatic tumors versus minimal normal tissue uptake. mAb 14C5 is a promising new antibody for targeting the integrin alpha(v)beta(5) for the diagnosis of and potential therapy for pancreatic cancer.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Pancreatic Neoplasms / therapy. Radiopharmaceuticals. Xenograft Model Antitumor Assays
  • [MeSH-minor] Animals. Drug Evaluation, Preclinical. Female. Humans. Iodine Radioisotopes. Mice. Mice, Nude. Pancreas / immunology. Pancreas / metabolism. Pancreas / pathology. Pentetic Acid / analogs & derivatives. Pentetic Acid / pharmacokinetics. Radioimmunoassay. Receptors, Vitronectin / immunology. Receptors, Vitronectin / metabolism. Tissue Distribution. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423233.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14C5 monoclonal antibody; 0 / Antibodies, Monoclonal; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Receptors, Vitronectin; 0 / integrin alphaVbeta5; 102650-30-6 / 1-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid; 7A314HQM0I / Pentetic Acid
  •  go-up   go-down


60. Zhang XP, Tian H, Lai YH, Chen L, Zhang L, Cheng QH, Yan W, Li Y, Li QY, He Q, Wang F: Protective effects and mechanisms of Baicalin and octreotide on renal injury of rats with severe acute pancreatitis. World J Gastroenterol; 2007 Oct 14;13(38):5079-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mortality, plasma endotoxin level, contents of blood urea nitrogen (BUN), creatinine (CREA), phospholipase A2 (PLA2), nitrogen monoxide (NO), tumor necrosis factor (TNF)-alpha, IL-6 and endothelin-1 (ET-1) in serum, expression levels of renal Bax and Bcl-2 protein, apoptotic indexes and pathological changes of kidney were observed at 3, 6 and 12 h after operation.
  • The contents of IL-6, ET-1, TNF-alpha (at 6 h) and PLA2 (at 6 h and 12 h) were lower in treated groups than in model group [P<0.001, 3.031 (0.870) and 2.646 (1.373) pg/mL vs 5.437 (1.025) pg/mL; 2.882 (1.392) and 3.076 (1.205) pg/mL vs 6.817 (0.810) pg/mL; 2.832 (0.597) and 2.462 (1.353) pg/mL vs 5.356 (0.747) pg/mL; 16.226 (3.174) and 14.855 (5.747) pg/mL vs 25.625 (7.973) pg/mL; 18.625 (5.780) and 15.185 (1.761) pg/mL vs 24.725 (3.759) pg/mL; 65.10 (27.51) and 47.60 (16.50) pg/mL vs 92.15 (23.12) pg/mL; 67.91+/-20.61 and 66.86+/-22.10 U/mL, 63.13+/-26.31 and 53.63+/-12.28 U/mL vs 101.46+/-14.67 and 105.33+/-18.10 U/mL, respectively].
  • [MeSH-minor] Acute Disease. Animals. Apoptosis / drug effects. Creatinine / blood. Dose-Response Relationship, Drug. Endothelin-1 / blood. Interleukin-6 / blood. Male. Nitric Oxide / blood. Phospholipases A2 / blood. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rats. Rats, Sprague-Dawley. Tumor Necrosis Factor-alpha / blood. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876873.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Bax protein, rat; 0 / Endothelin-1; 0 / Flavonoids; 0 / Gastrointestinal Agents; 0 / Interleukin-6; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Necrosis Factor-alpha; 0 / bcl-2-Associated X Protein; 31C4KY9ESH / Nitric Oxide; 347Q89U4M5 / baicalin; AYI8EX34EU / Creatinine; EC 3.1.1.4 / Phospholipases A2; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC4434637
  •  go-up   go-down


61. Korkolis DP, Aggeli C, Plataniotis GD, Gontikakis E, Zerbinis H, Papantoniou N, Xinopoulos D, Apostolikas N, Vassilopoulos PP: Successful en bloc resection of primary hepatocellular carcinoma directly invading the stomach and pancreas. World J Gastroenterol; 2009 Mar 7;15(9):1134-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful en bloc resection of primary hepatocellular carcinoma directly invading the stomach and pancreas.
  • Multivisceral surgical resection for cure was successfully performed in a 70-year-old man suffering from a primary hepatocellular carcinoma (HCC) associated with direct invasion to the stomach and pancreas.
  • The patient presented with gastric outlet obstruction, upper abdominal pain and a history of chronic liver disease due to hepatitis B virus (HBV) infection.
  • Upper gastrointestinal (GI) endoscopy revealed an infiltrating tumor protruding through the gastric wall and obliterating the lumen.
  • Computer tomograghy (CT) and magnetic resonance imaging (MRI) scan demonstrated a 15-cm tumor in the left lateral segment of the liver with invasion to the stomach and pancreas.
  • Alpha-foetoprotein (AFP) levels and liver function tests were normal.
  • Pathology revealed a poorly differentiated, giant cell HCC involving the stomach and pancreas.
  • Disease-free margins of resection were achieved.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol Hepatol. 2000 May;15(5):536-41 [10847441.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(6):441-4 [15619024.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(3):339-44 [10982638.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(3):393-6 [12353155.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):1034-6 [12845974.001]
  • [Cites] Endoscopy. 1987 Jan;19(1):37-8 [3030716.001]
  • [Cites] Endoscopy. 1990 May;22(3):118-23 [2162757.001]
  • [Cites] J Gastroenterol Hepatol. 1994 Sep-Oct;9(5):533-5 [7827310.001]
  • [Cites] Dig Dis Sci. 1995 Dec;40(12):2516-21 [8536505.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):765-7 [8872775.001]
  • [Cites] Eur J Surg Oncol. 1996 Oct;22(5):516-20 [8903496.001]
  • [Cites] Jpn J Clin Oncol. 1997 Oct;27(5):343-5 [9390214.001]
  • [Cites] J Clin Gastroenterol. 1997 Jul;25(1):373-5 [9412926.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(1):90-3 [10436243.001]
  • [Cites] Abdom Imaging. 2000 Jul-Aug;25(4):380-4 [10926190.001]
  • (PMID = 19266609.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2655177
  •  go-up   go-down


62. Qu CF, Song EY, Li Y, Rizvi SM, Raja C, Smith R, Morgenstern A, Apostolidis C, Allen BJ: Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin Exp Metastasis; 2005;22(7):575-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.
  • PURPOSE: The urokinase plasminogen activator (uPA) and its receptor (uPAR) are expressed by pancreatic cancer cells and can be targeted by the plasminogen activator inhibitor type 2 (PAI2).
  • We have labeled PAI2 with (213)Bi to form the alpha conjugate (AC), and have studied its in vitro cytotoxicity and in vivo efficacy.
  • METHODS AND MATERIALS: The expression of uPA/uPAR on pancreatic cell lines, human pancreatic cancer tissues, lymph node metastases, and mouse xenografts were detected by immunohistochemistry, confocal microscopy, and flow cytometry.
  • At 2 days post-cancer cell subcutaneous inoculation, mice were injected with AC by local or systemic injection.
  • RESULTS: uPA/uPAR is strongly expressed on pancreatic cancer cell lines and cancer tissues.
  • The AC can target and kill cancer cells in vitro in a concentration-dependent fashion.
  • Some 90% of TUNEL positive cells were found after incubation with 1.2 MBq/ml of AC.
  • A single local injection of approximately 222 MBq/kg 2 days post-cell inoculation can completely inhibit tumor growth over 12 weeks, and an intraperitoneal injection of 111 MBq/kg causes significant tumor growth delay.
  • CONCLUSIONS: (213)Bi-PAI2 can specifically target pancreatic cancer cells in vitro and inhibit tumor growth in vivo. (213)Bi-PAI2 may be a useful agent for the treatment of post-surgical pancreatic cancer patients with minimum residual disease.
  • [MeSH-major] Bismuth / therapeutic use. Neoplasm Metastasis / radiotherapy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / radiotherapy. Plasminogen Activator Inhibitor 2 / therapeutic use. Radioisotopes / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival / radiation effects. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Mice. Microscopy, Confocal. Radiopharmaceuticals / therapeutic use. Transplantation, Heterologous. Urokinase-Type Plasminogen Activator / metabolism

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med. 1998 Sep;25(9):1341-51 [9724387.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] J Nucl Med. 2002 May;43(5):693-713 [11994535.001]
  • [Cites] Mutat Res. 1996 Nov;366(2):171-9 [9001584.001]
  • [Cites] Br J Cancer. 1997;75(3):388-95 [9020484.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4489-97 [15240541.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):274-85 [15791436.001]
  • [Cites] Pancreas. 1998 Apr;16(3):238-42 [9548661.001]
  • [Cites] Phys Med Biol. 2004 Aug 21;49(16):3703-12 [15446799.001]
  • [Cites] Clin Exp Metastasis. 1995 Mar;13(2):116-22 [7882614.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1259-66 [10942366.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1197-203 [11953871.001]
  • [Cites] Nucl Med Commun. 1999 Mar;20(3):205-7 [10093068.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1233-9 [12149203.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):205-9 [7816818.001]
  • [Cites] Nucl Med Commun. 1996 Jan;17(1):40-7 [8692472.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):175-84 [10389994.001]
  • [Cites] Oncogene. 1999 Aug 12;18(32):4554-63 [10467400.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4676-84 [2114945.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3304s-3314s [10541379.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4007-24 [7492756.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):618-26 [14991585.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Exp Cell Res. 2004 Jul 1;297(1):259-71 [15194441.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] Am J Gastroenterol. 1993 Nov;88(11):1928-33 [8237943.001]
  • [Cites] Int J Radiat Biol. 1994 Nov;66(5):427-32 [7983426.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):195-201 [11418316.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jan;71(2):149-59 [11881911.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):944-50 [12644835.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3753-61 [1712249.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):547-54 [14722680.001]
  • [Cites] Adv Cancer Res. 1991;57:273-328 [1950706.001]
  • [Cites] Radiat Res. 1992 May;130(2):220-6 [1574578.001]
  • (PMID = 16475028.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Plasminogen Activator Inhibitor 2; 0 / Radioisotopes; 0 / Radiopharmaceuticals; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; U015TT5I8H / Bismuth
  •  go-up   go-down


63. Wei H, Wang C, Chen L: Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1alpha. Pancreas; 2006 Mar;32(2):159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1alpha.
  • OBJECTIVE: Hypoxia-inducible factor 1alpha (HIF-1alpha) has been universally detected in many types of cells and plays a key role in modulation of tumor-related genes.
  • The purpose of this study was to explore the relationship between HIF-1alpha messenger RNA (mRNA) expression and biologic characteristics in pancreatic cancer, such as tumor angiogenesis, tumor cell proliferation, differentiation, apoptosis, and metastasis.
  • The expressions of survivin, proliferating cell nuclear antigen (PCNA), and CD34 proteins were measured immunohistochemically.
  • RESULTS: There was very significant difference in the expression of HIF-1alpha between the pancreatic cancer tissue and adjacent normal tissue (P < 0.01), but no significant difference was found among tumor histopathologic grades (P > 0.05).
  • There was significant difference in the expression of HIF-1alpha mRNA between Japanese Pancreatic Society stages I to II and stages III to IV (P < 0.05).
  • CONCLUSION: The expression level of HIF-1alpha mRNA is surmised to have a significant correlation with tumor angiogenesis, cell proliferation, apoptosis, and metastasis.
  • Inhibition of HIF-1alpha may be an important and approachable therapeutic target for pancreatic cancer.
  • [MeSH-major] Antigens, CD34 / genetics. Microtubule-Associated Proteins / genetics. Neoplasm Proteins / genetics. Pancreatic Neoplasms / genetics. Proliferating Cell Nuclear Antigen / genetics
  • [MeSH-minor] DNA Primers. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / genetics. Inhibitor of Apoptosis Proteins. Neoplasm Staging. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552335.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / BIRC5 protein, human; 0 / DNA Primers; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


64. Tapia B, Ahrens W, Kenney B, Touloukian R, Reyes-Múgica M: Acinar cell carcinoma versus solid pseudopapillary tumor of the pancreas in children: a comparison of two rare and overlapping entities with review of the literature. Pediatr Dev Pathol; 2008 Sep-Oct;11(5):384-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma versus solid pseudopapillary tumor of the pancreas in children: a comparison of two rare and overlapping entities with review of the literature.
  • Primary epithelial tumors of the pancreas are extremely uncommon in children, and among these, acinar cell carcinoma (ACC) is the most rare.
  • Here we describe our recent observations in the case of a 10-year-old boy with one of these exceptional examples.
  • The histologic diagnosis of ACC was supported by both immunohistochemistry and electron microscopy.
  • Despite its rarity, ACC should be kept in the differential diagnosis of pediatric pancreatic exocrine tumors.
  • We also provide a comparison with an example of solid pseudopapillary tumor, another relatively infrequent epithelial tumor of the pancreas in the young.
  • We review the relevant literature addressing the clinical and pathologic features of ACC and its distinction from other pancreatic neoplasms.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Pancreatic Cyst / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Child. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Pancreatectomy. Treatment Outcome. alpha 1-Antitrypsin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006424.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPINA1 protein, human; 0 / alpha 1-Antitrypsin
  • [Number-of-references] 37
  •  go-up   go-down


65. Gin VC, Zacharias M: Glucagonoma: anaesthetic management. Anaesth Intensive Care; 2009 Mar;37(2):329-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucagonoma: anaesthetic management.
  • [MeSH-major] Anesthesia, General / methods. Glucagonoma / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Blood Glucose / analysis. Female. Glucagon / blood. Humans. Middle Aged

  • Genetic Alliance. consumer health - Glucagonoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19400510.001).
  • [ISSN] 0310-057X
  • [Journal-full-title] Anaesthesia and intensive care
  • [ISO-abbreviation] Anaesth Intensive Care
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Blood Glucose; 9007-92-5 / Glucagon
  •  go-up   go-down


66. Li YH, Huang ZW, Xue P, Guo J, He FQ, You Z, Wang ZR: [Effects of Chaiqin Chengqi Decoction on activation of nuclear factor-kappaB in pancreas of rats with acute necrotizing pancreatitis]. Zhong Xi Yi Jie He Xue Bao; 2008 Feb;6(2):180-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of Chaiqin Chengqi Decoction on activation of nuclear factor-kappaB in pancreas of rats with acute necrotizing pancreatitis].
  • Blood sample was collected from abdominal vein for examination and the pancreatic tissue samples were taken for making pathology section 6 hours later.
  • The pancreatic tissue (HE staining) was observed by light microscope.
  • The content of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) was detected with the method of enzyme-linked immunosorbent assay, and the activation of nuclear factor-kappaB (NF-kappaB) in pancreas was detected by immunohistochemical method.
  • RESULTS: Compared with the SO group, there was dramatic increase in the white blood cell (WBC) counts and AMY level in the ANP group (P<0.05, P<0.01).
  • The integral optical density of NF-kappaB p65 positive cells of pancreas in CQCQD-treated group was lower than that in the ANP group (P<0.05).
  • CONCLUSION: CQCQD can reduce the content of serum TNF-alpha and IL-6, depress the activation of NF-kappaB, and lessen the pancreatic lesions.
  • [MeSH-major] Drugs, Chinese Herbal / therapeutic use. NF-kappa B / metabolism. Pancreas / metabolism. Pancreatitis, Acute Necrotizing / drug therapy. Phytotherapy
  • [MeSH-minor] Animals. Female. Interleukin-6 / blood. Male. Random Allocation. Rats. Rats, Sprague-Dawley. Tumor Necrosis Factor-alpha / blood

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241655.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chai Qin Cheng Qi decoction; 0 / Drugs, Chinese Herbal; 0 / Interleukin-6; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


67. Mukherjee S, Das D, Mukherjee M, Das AS, Mitra C: Synergistic effect of folic acid and vitamin B12 in ameliorating arsenic-induced oxidative damage in pancreatic tissue of rat. J Nutr Biochem; 2006 May;17(5):319-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic effect of folic acid and vitamin B12 in ameliorating arsenic-induced oxidative damage in pancreatic tissue of rat.
  • The efficacies of two nutritional factors, folic acid and vitamin B12, were assessed in this study against arsenic-induced islet cellular toxicity.
  • Results showed that, compared to control group, there was a significant increase in the levels of nitric oxide (NO), malondialdehyde (MDA) and hydroxyl radical (OH-) formation in the pancreatic tissue of arsenic-treated rats, while the activity of antioxidant enzymes, superoxide dismutase (SOD) and catalase (CAT), and cellular content of antioxidant glutathione (GSH) were low in these animals.
  • The serum level of tumor necrosis factor-alpha (TNF-alpha) and IL-6 was significantly high in these animals.
  • Light microscopic examination showed a marked fall in the number of islet cells.
  • Although folic acid alone could not restore the normal level of TNF-alpha and IL-6, combined folic acid and vitamin B12 could restore it.
  • Folic acid and vitamin B12 combined also could recover islet cell count.
  • [MeSH-major] Arsenic / toxicity. Folic Acid / administration & dosage. Oxidative Stress / drug effects. Pancreas / drug effects. Vitamin B 12 / administration & dosage
  • [MeSH-minor] Animals. Catalase / metabolism. Drug Synergism. Glutathione / analysis. Hydroxyl Radical / metabolism. Interleukin-6 / blood. Islets of Langerhans / cytology. Islets of Langerhans / drug effects. Male. Malondialdehyde / metabolism. Nitric Acid / metabolism. Rats. Superoxide Dismutase / metabolism. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Hazardous Substances Data Bank. NITRIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16214333.001).
  • [ISSN] 0955-2863
  • [Journal-full-title] The Journal of nutritional biochemistry
  • [ISO-abbreviation] J. Nutr. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 3352-57-6 / Hydroxyl Radical; 411VRN1TV4 / Nitric Acid; 4Y8F71G49Q / Malondialdehyde; 935E97BOY8 / Folic Acid; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione; N712M78A8G / Arsenic; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


68. Li Z, Fallon J, Mandeli J, Wetmur J, Woo SL: A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Natl Cancer Inst; 2008 Oct 1;100(19):1389-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer.
  • BACKGROUND: A major obstacle in treatment of solid tumors is the inefficient delivery of therapeutic agents to the hypoxic cores.
  • Hypoxia offers the potential for anaerobic bacteria colonization and tumor destruction by the bacteria, and dormant spores of wild-type Clostridium perfringens (Cp) germinate and proliferate within the hypoxic cores of pancreatic tumors in mice.
  • METHODS: Recombinant Cp strains in which superoxide dismutase, a major oxygen tolerance gene, was deleted (Cp/sod(-)) were constructed to enhance its selective growth in tumors.
  • The ability of the recombinant Cp strains to kill tumors was investigated in C57/BL6 mice bearing murine PANC02 tumors.
  • RESULTS: Cp/sod(-) showed reduced toxic effects compared with wild-type Cp when spores were administered intravenously into PANC02 tumor-bearing mice.
  • Mice treated with Cp/sod(-)/PVL spores demonstrated a reduction in neutrophils and macrophages in tumors, logarithmically elevated growth of intratumoral bacteria, enhanced tumor necrosis, and substantially prolonged survival without apparent systemic and organ toxic effects, compared with mice treated with both wild-type Cp and Cp/sod(-) spores.
  • Accordingly, 47% of Cp/sod(-)/PVL-treated mice (n = 15) achieved tumor-free survival for over 120 days, whereas all mice treated with Cp/sod(-) or phosphate-buffered saline (n = 10 per group) died within 50 days.
  • CONCLUSIONS: Cp/sod(-)/PVL provides a prototype for a novel class of oncopathic microbes that may have potential for the safe and effective treatment of pancreatic cancer and other poorly vascularized tumors.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] NIH Guide Grants Contracts. 2016 Jul 29;:NOT-OD-16-124 [27483554.001]
  • [RetractionIn] Li Z, Fallon J, Mandeli J, Wetmur J, Woo SL. J Natl Cancer Inst. 2010 Feb 24;102(4):283 [20176752.001]
  • [CommentIn] Fed Regist. 2016 Jul 25;81(142):48426-48427 [27737274.001]
  • (PMID = 18812551.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-120017
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Toxins; 0 / Biomarkers, Tumor; 0 / Exotoxins; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Leukocidins; 0 / Panton-Valentine leukocidin; EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ PMC2720732
  •  go-up   go-down


69. Graham KL, Sanders N, Tan Y, Allison J, Kay TW, Coulson BS: Rotavirus infection accelerates type 1 diabetes in mice with established insulitis. J Virol; 2008 Jul;82(13):6139-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection modulates type 1 diabetes, a common autoimmune disease characterized by the destruction of insulin-producing islet beta cells in the pancreas.
  • Childhood rotavirus infections have been associated with exacerbations in islet autoimmunity.
  • Nonobese diabetic (NOD) mice develop lymphocytic islet infiltration (insulitis) and then clinical diabetes, whereas NOD8.3 TCR mice, transgenic for a T-cell receptor (TCR) specific for an important islet autoantigen, show more rapid diabetes onset.
  • Infected males showed increased CD8(+) T-cell proportions in islets.
  • Levels of beta-cell major histocompatibility complex class I expression and islet tumor necrosis factor alpha mRNA were elevated in at least one model.
  • Thus, rotavirus infection after beta-cell autoimmunity is established affects insulitis and exacerbates diabetes.
  • A possible mechanism involves increased exposure of beta cells to immune recognition and activation of autoreactive T cells by proinflammatory cytokines.
  • [MeSH-minor] Age Factors. Analysis of Variance. Animals. Antibodies, Viral / blood. CD8-Positive T-Lymphocytes / immunology. Flow Cytometry. Male. Mice. Mice, Inbred BALB C. Mice, Inbred NOD. Receptors, Antigen, T-Cell / genetics. Receptors, Antigen, T-Cell / immunology


70. Chong MM, Metcalf D, Jamieson E, Alexander WS, Kay TW: Suppressor of cytokine signaling-1 in T cells and macrophages is critical for preventing lethal inflammation. Blood; 2005 Sep 1;106(5):1668-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppressor of cytokine signaling-1 in T cells and macrophages is critical for preventing lethal inflammation.
  • Here, cre/loxP deletion of Socs1 was used to investigate the contribution of specific cells/tissues to inflammatory disease.
  • Mice with SOCS-1 deficiency in myeloid and lymphoid cells, but not lymphoid alone, became ill at 50 to 250 days of age.
  • These mice developed splenomegaly and T-cell/macrophage infiltration of many organs, including liver, lung, pancreas, and muscle.
  • There were also abnormally high levels of the proinflammatory cytokines interferon gamma (IFN-gamma), tumor necrosis factor (TNF), and interleukin-12 (IL-12), and activated T cells circulating in these mice.
  • Socs1(null) T cells were found to be hypersensitive to multiple cytokines, including IL-1, IL-2, and IL-12, resulting in IFN-gamma production without requiring T-cell receptor (TCR) ligation.
  • A dysregulated cytokine network between T cells and macrophages is thus associated with this inflammatory disease.
  • These findings indicate that SOCS-1 is critical in both T cells and macrophages for preventing uncontrolled inflammation.
  • [MeSH-minor] Animals. Cell Lineage / drug effects. Cell Lineage / immunology. Dose-Response Relationship, Drug. Interferon-gamma / pharmacology. Lipopolysaccharides / pharmacology. Mice. Mice, Transgenic. Myeloid Progenitor Cells / drug effects. Myeloid Progenitor Cells / immunology. Suppressor of Cytokine Signaling Proteins. Tumor Necrosis Factor-alpha / pharmacology

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899915.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Carrier Proteins; 0 / Lipopolysaccharides; 0 / Repressor Proteins; 0 / Socs1 protein, mouse; 0 / Suppressor of Cytokine Signaling Proteins; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


71. Samuel I, Tephly L, Williard DE, Carter AB: Enteral exclusion increases MAP kinase activation and cytokine production in a model of gallstone pancreatitis. Pancreatology; 2008;8(1):6-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We have previously demonstrated that enteral exclusion augments pancreatic p38 mitogen-activated protein (MAP) kinase activation and tumor necrosis factor-alpha (TNF-alpha) production after bile-pancreatic duct ligation in rats.
  • METHODS: In the present study, we evaluated c-Jun NH(2)-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation, and cytokine production, in pancreata of duct-ligated rats with and without duodenal bile-pancreatic juice replacement from a donor rat.
  • We hypothesized that enteral exclusion of bile-pancreatic juice activates stress kinases and induces cytokine production in ligation-induced acute pancreatitis.
  • RESULTS: Increased JNK and ERK activation after ligation are inhibited by bile-pancreatic juice replacement.
  • Increases in pancreatic production of IL-1beta and IL-12 after ligation are significantly subdued by replacement.
  • In additional in vitro studies, we show that cholecystokinin- or TNF-alpha-stimulated nuclear transcription factor kappa-B activation in AR42J cells is inhibited by dominant negative ERK2.
  • CONCLUSIONS: Our novel findings using our Donor Rat Model indicate that bile-pancreatic juice exclusion induces MAP kinase activation and exacerbates cell stress and inflammation in this experimental model of gallstone pancreatitis. and IAP.

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • [Cites] J Gastroenterol. 2000;35(1):1-9 [10632533.001]
  • [Cites] Pancreatology. 2005;5(1):20-6 [15775695.001]
  • [Cites] Physiol Rev. 2001 Apr;81(2):807-69 [11274345.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):18934-40 [11259436.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30188-98 [11402028.001]
  • [Cites] Dig Dis Sci. 2001 Sep;46(9):1871-81 [11575438.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):448-57 [11832459.001]
  • [Cites] World J Gastroenterol. 2001 Apr;7(2):259-65 [11819771.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S81-96 [11983155.001]
  • [Cites] J Gastrointest Surg. 2001 Nov-Dec;5(6):661-72 [12086906.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):639-51 [16083718.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Nov;289(5):G926-34 [16051920.001]
  • [Cites] J Gastrointest Surg. 2006 Jul-Aug;10(7):950-9 [16843865.001]
  • [Cites] J Gastrointest Surg. 2006 Dec;10(10):1376-83 [17175457.001]
  • [Cites] Pancreatology. 2006;6(6):542-8 [17124436.001]
  • [Cites] Pancreatology. 2007;7(5-6):436-46 [17898533.001]
  • [Cites] Surgery. 2008 Mar;143(3):434-40 [18291265.001]
  • [Cites] Pancreatology. 2002;2(1):46-53 [12120007.001]
  • [Cites] Pancreas. 2002 Oct;25(3):251-9 [12370536.001]
  • [Cites] Pancreatology. 2002;2(6):503-9 [12435862.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):20-5 [12559181.001]
  • [Cites] Am J Surg. 2003 Nov;186(5):569-74 [14599627.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1010:104-8 [15033703.001]
  • [Cites] Pancreatology. 2004;4(1):49-56 [14988658.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Sep;287(3):G582-91 [15117677.001]
  • [Cites] Surg Gynecol Obstet. 1974 Jul;139(1):69-81 [4834279.001]
  • [Cites] Am J Gastroenterol. 1982 Sep;77(9):633-8 [7051819.001]
  • [Cites] Dig Dis Sci. 1985 Jun;30(6):575-81 [3996161.001]
  • [Cites] J Neurochem. 1991 Aug;57(2):483-90 [1712830.001]
  • [Cites] Am J Surg. 1995 Apr;169(4):391-9 [7535017.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):207-11 [8554143.001]
  • [Cites] Biochemistry. 1996 May 21;35(20):6283-8 [8639570.001]
  • [Cites] Surgery. 1997 Aug;122(2):295-301; discussion 301-2 [9288135.001]
  • [Cites] Am J Surg. 1998 Jan;175(1):76-83 [9445247.001]
  • [Cites] Shock. 1998 Sep;10(3):169-75 [9744644.001]
  • [Cites] Hepatology. 1998 Nov;28(5):1282-8 [9794913.001]
  • [Cites] Digestion. 1999;60 Suppl 1:27-33 [10026428.001]
  • [Cites] Surgery. 1999 Aug;126(2):216-22 [10455887.001]
  • [Cites] Surg Clin North Am. 1999 Aug;79(4):699-710 [10470320.001]
  • [Cites] Am J Surg. 2004 Nov;188(5):511-5 [15546560.001]
  • [Cites] Pancreatology. 2004;4(6):527-32 [15334004.001]
  • [Cites] J Cell Mol Med. 2005 Jan-Mar;9(1):59-71 [15784165.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Jan;278(1):G165-72 [10644575.001]
  • (PMID = 18235211.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK062805; United States / NIEHS NIH HHS / ES / R01 ES014871; United States / NIDDK NIH HHS / DK / DK062805
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cytokines; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2829292
  •  go-up   go-down


72. Kitamura Y, Sato M, Hatamochi A, Yamazaki S: Necrolytic migratory erythema without glucagonoma associated with hepatitis B. Eur J Dermatol; 2005 Jan-Feb;15(1):49-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Necrolytic migratory erythema without glucagonoma associated with hepatitis B.
  • We report a case of necrolytic migratory erythema (NME) without glucagonoma associated with hepatitis B.
  • Although the most common cause of NME is a glucagon-secreting alpha-islet cell tumor of the pancreas, a dermatitis clinically and histologicaly identical to NME has been described in patients without glucagonoma.
  • We added some discussion on the terminology of this disease.

  • Genetic Alliance. consumer health - Glucagonoma.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701595.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


73. Prout TM, Taylor AJ: Case of the season: glucagonoma syndrome. Semin Roentgenol; 2005 Jan;40(1):4-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of the season: glucagonoma syndrome.
  • [MeSH-major] Glucagonoma / radiography. Pancreatic Neoplasms / radiography
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Syndrome. Tomography, X-Ray Computed


74. Marogy G, De Man M, Verslype C: Necrolytic migratory erythaema and glucagonoma syndrome. Acta Clin Belg; 2009 Jan-Feb;64(1):70-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Necrolytic migratory erythaema and glucagonoma syndrome.
  • [MeSH-major] Erythema / etiology. Glucagonoma / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Syndrome


75. Oberg K: Pancreatic endocrine tumors. Semin Oncol; 2010 Dec;37(6):594-618
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors.
  • Pancreatic endocrine tumors have been steadily growing in incidence and prevalence during the last two decades, showing an incidence of 4-5/1,000,000 population.
  • They represent a heterogeneous group with very varying tumor biology and prognosis.
  • About half of the patients present clinical symptoms and syndromes related to substances released from the tumors (Zollinger-Ellison syndrome, insulinoma, glucagonoma, etc) and the other half are so-called nonfunctioning tumors mainly presenting with symptoms such as obstruction, jaundice, bleeding, and abdominal mass.
  • Ten percent to 15% of the pancreatic endocrine tumors are part of an inherited syndrome such as multiple endocrine neoplasia type 1 (MEN-1), von Hippel-Lindau (VHL), neurofibromatosis, or tuberousclerosis.
  • The diagnosis is based on histopathology demonstrating neuroendocrine features such as positive staining for chromogranin A and specific hormones such as gastrin, proinsulin, and glucagon.
  • Moreover, the biochemical diagnosis includes measurement of chromogranins A and B or specific hormones such as gastrin, insulin, glucagon, and vasoactive intestinal polypeptide (VIP) in the circulation.
  • Surgery is still one of the cornerstones in the management of pancreatic endocrine tumors, but curative surgery is rarely obtained in most cases because of metastatic disease.
  • Cytotoxic drugs, biological agents, such as somatostatin analogs, alpha interferons, mammalian target of rapamycin (mTOR) inhibitors and tyrosine kinase inhibitors are routinely used.
  • Tumor-targeted radioactive treatment is available in many centres in Europe and is effective in patients with tumors that express high content of somatostatin receptors type 2 and 5.
  • In the future, treatment will be based on tumor biology and molecular genetics with the aim of so-called personalized medicine.
  • [MeSH-major] Pancreatic Neoplasms
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biological Therapy / methods. Biomarkers, Tumor. Humans. Neoplastic Syndromes, Hereditary / diagnosis. Neoplastic Syndromes, Hereditary / therapy. Pancreatectomy. Paraneoplastic Endocrine Syndromes / diagnosis. Paraneoplastic Endocrine Syndromes / therapy


76. Sun LK, Reding T, Bain M, Heikenwalder M, Bimmler D, Graf R: Prostaglandin E2 modulates TNF-alpha-induced MCP-1 synthesis in pancreatic acinar cells in a PKA-dependent manner. Am J Physiol Gastrointest Liver Physiol; 2007 Dec;293(6):G1196-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostaglandin E2 modulates TNF-alpha-induced MCP-1 synthesis in pancreatic acinar cells in a PKA-dependent manner.
  • We recently demonstrated in a model of chronic pancreatitis (WBN/Kob rat) that inhibition of COX-2 activity reduces and delays pancreatic inflammation and fibrosis.
  • MCP-1 plays an important role in the recruitment of macrophages to the site of tissue injury.
  • The aim of our study is to identify mechanisms by which macrophages and acinar cells maintain an inflammatory reaction.
  • The expression profile of E prostanoid receptors EP(1-4) and MCP-1 was analyzed by RT-PCR from pancreatic specimens and AR42J cells.
  • MCP-1 secretion was detected by ELISA from rat pancreatic lobuli.
  • We determined EP(1-4) mRNA levels in WBN/Kob rats with chronic pancreatic inflammation.
  • Individual isoforms were highly increased in rat pancreas, concurrent with MCP-1 mRNA expression.
  • In supernatants of pancreatic lobuli and AR42J cells, MCP-1 was detectable by ELISA.
  • In the presence of TNF-alpha, MCP-1 was upregulated.
  • Coincubation with PGE(2) enhanced the TNF-alpha-induced MCP-1 synthesis significantly.
  • Similarly, TNF-alpha mRNA was synergistically upregulated by TNF-alpha and PGE(2).
  • Furthermore, the synergistic effect of TNF-alpha and PGE(2) was abolished by inhibition of PKA but not of PKC.
  • We conclude that EP receptors are upregulated during chronic pancreatic inflammation.
  • PGE(2) modulates the TNF-alpha-induced MCP-1 synthesis and secretion from acinar cells.
  • This mechanism might explain the COX-2-dependent propagation of pancreatic inflammation.
  • [MeSH-major] Chemokine CCL2 / metabolism. Cyclic AMP-Dependent Protein Kinases / metabolism. Dinoprostone / metabolism. Pancreas / metabolism. Pancreatitis / metabolism. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Animals. Cell Line. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916652.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ccl2 protein, rat; 0 / Chemokine CCL2; 0 / Tumor Necrosis Factor-alpha; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


77. Tascilar O, Cakmak GK, Tekin IO, Emre AU, Ucan BH, Bahadir B, Acikgoz S, Irkorucu O, Karakaya K, Balbaloglu H, Kertis G, Ankarali H, Comert M: Protective effects of erythropoietin against acute lung injury in a rat model of acute necrotizing pancreatitis. World J Gastroenterol; 2007 Dec 14;13(46):6172-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue levels of TNF-alpha, IL-2 and IL-6 were screened immunohistochemically.
  • The level of tumor necrosis factor-alpha (TNF-alpha) and IL-6 and accumulation of ox-LDL were evident in the lung tissues of ANP groups when compared to EPO groups, particularly at 72 h.
  • CONCLUSION: EPO administration leads to a significant decrease in ALI parameters by inhibiting polymorphonuclear leukocyte (PMNL) accumulation, decreasing the levels of proinflammatory cytokines in circulation, preserving microvascular endothelial cell integrity and reducing oxidative stress-associated lipid peroxidation and therefore, can be regarded as a cytoprotective agent in ANP-induced ALI.
  • [MeSH-major] Erythropoietin / pharmacology. Pancreatitis, Acute Necrotizing / complications. Respiratory Distress Syndrome, Adult / etiology. Respiratory Distress Syndrome, Adult / prevention & control
  • [MeSH-minor] Amylases / blood. Animals. Body Weight. Disease Models, Animal. Interleukin-2 / blood. Interleukin-6 / blood. Lipoproteins, LDL / metabolism. Lung / metabolism. Lung / pathology. Male. Malondialdehyde / metabolism. Neutrophils / pathology. Pleural Effusion. Pulmonary Alveoli / pathology. Rats. Rats, Wistar. Taurodeoxycholic Acid

  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069756.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Interleukin-6; 0 / Lipoproteins, LDL; 0 / oxidized low density lipoprotein; 11096-26-7 / Erythropoietin; 4Y8F71G49Q / Malondialdehyde; 516-50-7 / Taurodeoxycholic Acid; EC 3.2.1.- / Amylases
  • [Other-IDs] NLM/ PMC4171226
  •  go-up   go-down


78. Szabo G, Mandrekar P, Oak S, Mayerle J: Effect of ethanol on inflammatory responses. Implications for pancreatitis. Pancreatology; 2007;7(2-3):115-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Alcohol use alters inflammatory cell responses.
  • While alcohol has direct effects on pancreatic acinar cells, activation of inflammatory cells is a major component of the pathology of alcoholic pancreatitis.
  • Our results support the hypothesis that both acute alcohol intake in the presence of complex stimuli (such as necrotic cells) and chronic alcohol exposure result in hyper-responsiveness of monocytes to inflammatory signals and may contribute to increased inflammation in pancreatitis.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Alcohol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel and IAP.
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G232-41 [15976389.001]
  • [Cites] Alcohol Clin Exp Res. 2006 Jan;30(1):135-9 [16433741.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):265-8 [16446382.001]
  • [Cites] Dig Dis. 2005;23(3-4):222-31 [16508286.001]
  • [Cites] Dig Dis. 2005;23(3-4):232-40 [16508287.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):4258-66 [16547263.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12):7628-35 [16751410.001]
  • [Cites] J Immunol. 2000 Jan 15;164(2):558-61 [10623794.001]
  • [Cites] Gastroenterology. 2001 Feb;120(3):708-17 [11179245.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jun;280(6):G1197-208 [11352813.001]
  • [Cites] Alcohol Clin Exp Res. 2001 Sep;25(9):1360-7 [11584157.001]
  • [Cites] Eur J Immunol. 2001 Nov;31(11):3388-93 [11745357.001]
  • [Cites] Alcohol Clin Exp Res. 2001 Dec;25(12):1766-72 [11781510.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):15107-12 [11842086.001]
  • [Cites] Alcohol. 2002 May;27(1):53-61 [12062638.001]
  • [Cites] Pancreatology. 2001;1(4):356-62 [12120214.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2003 Aug;17(4):575-92 [12828956.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2003 Aug;17(4):593-612 [12828957.001]
  • [Cites] J Gastroenterol. 2003;38(7):623-8 [12898353.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 1;417(1):34-43 [12921777.001]
  • [Cites] Pancreas. 2003 Nov;27(4):286-90 [14576488.001]
  • [Cites] Scand J Gastroenterol. 2004 Mar;39(3):277-82 [15074399.001]
  • [Cites] Alcohol Clin Exp Res. 2004 May;28(5):824-8 [15166660.001]
  • [Cites] Crit Care Med. 2004 Aug;32(8):1759-63 [15286555.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):3398-407 [15322204.001]
  • [Cites] Hepatology. 1989 Mar;9(3):349-51 [2920991.001]
  • [Cites] Hepatology. 1991 Feb;13(2):267-76 [1995437.001]
  • [Cites] J Leukoc Biol. 1992 Dec;52(6):602-10 [1464732.001]
  • [Cites] J Clin Immunol. 1993 Jan;13(1):8-22 [8445046.001]
  • [Cites] Hepatology. 1993 Sep;18(3):576-80 [8359798.001]
  • [Cites] Surgery. 1994 Jan;115(1):31-8 [8284758.001]
  • [Cites] J Immunol. 1994 Jul 15;153(2):811-6 [8021515.001]
  • [Cites] J Leukoc Biol. 1995 Sep;58(3):342-50 [7665990.001]
  • [Cites] Cytokine. 1996 Jul;8(7):567-77 [8891438.001]
  • [Cites] Am J Physiol. 1998 Oct;275(4 Pt 1):G605-11 [9756487.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 1):G1402-14 [9843778.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Dec;22(9):1927-42 [9884135.001]
  • [Cites] J Clin Immunol. 1999 Jan;19(1):67-76 [10080106.001]
  • [Cites] Int Immunol. 2005 Jan;17(1):1-14 [15585605.001]
  • [Cites] Am J Pathol. 2005 Jan;166(1):93-106 [15632003.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):167-74 [15704051.001]
  • [Cites] Adv Exp Med Biol. 2005;560:1-9 [15932015.001]
  • [Cites] Pancreas. 2005 Oct;31(3):251-7 [16163057.001]
  • [Cites] Alcohol Clin Exp Res. 2005 Nov;29(11 Suppl):102S-109S [16344593.001]
  • (PMID = 17592223.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R01 AA011576; United States / NIAAA NIH HHS / AA / AA00577; United States / NIAAA NIH HHS / AA / AA011576
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / TLR2 protein, human; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 4; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 3K9958V90M / Ethanol
  • [Number-of-references] 45
  • [Other-IDs] NLM/ PMC2790780
  •  go-up   go-down


79. Cao D, Antonescu C, Wong G, Winter J, Maitra A, Adsay NV, Klimstra DS, Hruban RH: Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations. Mod Pathol; 2006 Sep;19(9):1157-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations.
  • Solid-pseudopapillary neoplasms of the pancreas are uncommon neoplasms of low malignant potential and of uncertain histogenesis.
  • A small percentage of patients develop metastatic disease and some succumb to disease.
  • The management of patients with metastatic disease or unresectable tumor, and patients who are just not good surgical candidates is problematic.
  • Successful treatment of metastatic and unresectable gastrointestinal stromal tumors with KIT kinase inhibitor, imatinib mesylate (Gleevec), makes it intriguing to look at the status of KIT in solid-pseudopapillary neoplasms of the pancreas.
  • Of the 50 (50%) solid-pseudopapillary neoplasms, 25 showed diffuse expression (in >50% neoplastic cells) of KIT and additional five (10%) cases showed focal staining (in 10-50% neoplastic cells).
  • Expression of KIT was not associated with tumor behavior and prognosis.
  • Experience in gastrointestinal stromal tumors and other tumors have shown that mutation-mediated activation of KIT or PDGFRA is a prerequisite for clinical response with imatinib mesylate.
  • Thus, lack of mutations in KIT or PDGFRA in solid-pseudopapillary neoplasms suggests that imatinib mesylate is less likely to be effective in the treatment for patients with metastatic disease or unresectable tumor, and patients who are just not good surgical candidates.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Mutation. Pancreatic Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Receptor, Platelet-Derived Growth Factor alpha / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Cell Count. Child. DNA Mutational Analysis. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 16 June 2006.
  • (PMID = 16778826.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


80. Wang F, Larsson J, Herrington MK, Permert J: PP56 improves energy homeostasis in a mouse model of pancreatic cancer. Tumour Biol; 2010 Aug;31(4):309-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PP56 improves energy homeostasis in a mouse model of pancreatic cancer.
  • In this study, we investigated whether the anti-inflammatory drug PP56 (alpha-trinositol) may improve cancer-induced metabolic disorders.
  • We implanted human MiaPaCa2 pancreatic cancer cells in the pancreas of 14 athymic mice for 12 weeks, using six intact littermates as normal controls.
  • During the 12 weeks, seven tumor-cell recipients were treated with PP56 by daily injection (PPT mice).
  • The tumor-cell recipients that were otherwise untreated were used as tumor controls (TC mice).
  • When an enzyme for fatty acid beta-oxidation namely medium-chain acyl-CoA dehydrogenase (MCAD) was determined in tumor grafts; tumors from PPT mice showed more MCAD than those from TC mice.
  • This suggests that PP56 stimulated fatty acid beta-oxidation in MiaPaCa2 cells in vivo.
  • In vitro, we demonstrated that MiaPaCa2 cells consumed more fatty acids in the presence of PP56.
  • We also showed that PP56 increased glucose transport in L6 skeletal muscle cells in vitro.
  • In conclusion, PP56 increases the turnover of circulating nutrients such as glucose and helps maintain energy homeostasis in mice with pancreatic cancer.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Disease Models, Animal. Energy Metabolism / drug effects. Homeostasis / drug effects. Inositol Phosphates / pharmacology. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Acyl-CoA Dehydrogenase / metabolism. Animals. Blood Glucose / metabolism. Cells, Cultured. Fatty Acids / metabolism. Humans. Male. Mice. Mice, Inbred C57BL. Muscle, Skeletal / cytology. Muscle, Skeletal / drug effects. Muscle, Skeletal / metabolism. Rats

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 2003 Dec 8;115 Suppl 8A:29S-36S [14678863.001]
  • [Cites] Shock. 2003 Aug;20(2):149-53 [12865659.001]
  • [Cites] Diabetes. 1991 Feb;40(2):233-9 [1825073.001]
  • [Cites] Eur J Surg. 1993 Feb;159(2):101-7 [8098623.001]
  • [Cites] Diabetologia. 2006 Mar;49(3):562-70 [16447059.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Aug;64(3):517-27 [19112551.001]
  • [Cites] Eur J Pharmacol. 1993 Jun 24;237(2-3):257-63 [8365454.001]
  • [Cites] Am J Pathol. 2007 Feb;170(2):469-77 [17255315.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Apr;273(1):461-9 [7714802.001]
  • [Cites] Neuropeptides. 1992 Mar;21(3):163-6 [1630602.001]
  • [Cites] Gen Pharmacol. 1998 Nov;31(5):689-96 [9809464.001]
  • [Cites] Anesth Analg. 1998 Jan;86(1):107-10 [9428861.001]
  • (PMID = 20422342.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Blood Glucose; 0 / Fatty Acids; 0 / Inositol Phosphates; EC 1.3.8.7 / Acyl-CoA Dehydrogenase; VYF3049W3N / atrinositol
  •  go-up   go-down


81. Marsh WL, Colonna J, Yearsley M, Bloomston M, Frankel WL: Calponin is expressed in serous cystadenomas of the pancreas but not in adenocarcinomas or endocrine tumors. Appl Immunohistochem Mol Morphol; 2009 May;17(3):216-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calponin is expressed in serous cystadenomas of the pancreas but not in adenocarcinomas or endocrine tumors.
  • The diagnosis of serous microcystic adenoma (SMA) is usually straightforward.
  • For small biopsies and/or unusual variants, the differential diagnosis includes other pancreatic or metastatic neoplasms showing cystic or clear cell features.
  • We evaluated immunostains for potential use in the diagnosis of SMA.
  • Additionally, microarrays previously constructed from 56 pancreatic adenocarcinomas (PACs) and 64 pancreatic endocrine tumors (PENs) were studied.
  • The microarrays were stained with calponin, chromogranin, CD10, alpha-inhibin, and monoclonal neuron-specific enolase (m-NSE).
  • For SMAs, staining was seen with calponin (85.2%), alpha-inhibin (96.2%), and m-NSE (96.2%).
  • Staining for alpha-inhibin was absent in PACs and present in 4.1% of PENs; whereas immunoreactivity for m-NSE was present in 26.8% of PACs and 73.7% of PENs.
  • An immunohistochemical profile of staining with calponin, alpha-inhibin, and m-NSE and absent staining with chromogranin supports the diagnosis of SMA, and distinguishes SMA from PAC and PEN.
  • Calponin and alpha-inhibin are the most useful positive markers for SMA, and are negative in most entities in the differential diagnosis.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19391217.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / calponin; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


82. Clarke CJ, Guthrie JM, Hannun YA: Regulation of neutral sphingomyelinase-2 (nSMase2) by tumor necrosis factor-alpha involves protein kinase C-delta in lung epithelial cells. Mol Pharmacol; 2008 Oct;74(4):1022-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of neutral sphingomyelinase-2 (nSMase2) by tumor necrosis factor-alpha involves protein kinase C-delta in lung epithelial cells.
  • We have reported that p38 mitogen-activated protein kinase (MAPK) was upstream of nSMase2 in tumor necrosis-alpha (TNF-alpha)-stimulated A549 cells ( J Biol Chem 282: 1384-1396, 2007 ).
  • Pharmacological inhibition of PKCs prevented TNF-stimulated nSMase2 translocation to the PM in A549 cells.
  • Finally, down-regulation of PKC-delta inhibited induction of vascular cell and intercellular adhesion molecules, previously identified as downstream of nSMase2 in A549 cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18653803.001).
  • [ISSN] 1521-0111
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM043825; United States / NIGMS NIH HHS / GM / R37 GM043825; United States / NIGMS NIH HHS / GM / GM43825
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / NSMAF protein, human; 0 / RNA, Small Interfering; 0 / Tumor Necrosis Factor-alpha; EC 2.7.11.13 / Protein Kinase C-delta
  • [Other-IDs] NLM/ NIHMS710591; NLM/ PMC4698891
  •  go-up   go-down


83. Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, Nano R, Annunziata M, Campiglia P, Arnoletti E, Ghè C, Volante M, Papotti M, Muccioli G, Ghigo E: Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes; 2008 Apr;57(4):967-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function.
  • We investigated obestatin effect on survival of beta-cells and human pancreatic islets and the underlying signaling pathways.
  • RESEARCH DESIGN AND METHODS: beta-Cells and human islets were used to assess obestatin effect on cell proliferation, survival, apoptosis, intracellular signaling, and gene expression.
  • RESULTS: Obestatin showed specific binding on HIT-T15 and INS-1E beta-cells, bound to glucagon-like peptide-1 receptor (GLP-1R), and recognized ghrelin binding sites.
  • Obestatin exerted proliferative, survival, and antiapoptotic effects under serum-deprived conditions and interferon-gamma/tumor necrosis factor-alpha/interleukin-1 beta treatment, particularly at pharmacological concentrations.
  • Ghrelin receptor antagonist [D-Lys(3)]-growth hormone releasing peptide-6 and anti-ghrelin antibody prevented obestatin-induced survival in beta-cells and human islets. beta-Cells and islet cells released obestatin, and addition of anti-obestatin antibody reduced their viability.
  • Obestatin increased beta-cell cAMP and activated extracellular signal-related kinase 1/2 (ERK1/2) and phosphatidylinositol 3-kinase (PI 3-kinase)/Akt; its antiapoptotic effect was blocked by inhibition of adenylyl cyclase/cAMP/protein kinase A (PKA), PI 3-kinase/Akt, and ERK1/2 signaling.
  • The GLP-1R antagonist exendin-(9-39) reduced obestatin effect on beta-cell survival.
  • In human islets, obestatin, whose immunoreactivity colocalized with that of ghrelin, promoted cell survival and blocked cytokine-induced apoptosis through cAMP increase and involvement of adenylyl cyclase/cAMP/PKA signaling.
  • 2) stimulated insulin secretion and gene expression; and 3) upregulated GLP-1R, IRS-2, pancreatic and duodenal homeobox-1, and glucokinase mRNA.
  • CONCLUSIONS: These results indicate that obestatin promotes beta-cell and human islet cell survival and stimulates the expression of main regulatory beta-cell genes, identifying a new role for this peptide within the endocrine pancreas.
  • [MeSH-major] Cell Survival / drug effects. Gene Expression Regulation / drug effects. Insulin-Secreting Cells / cytology. Islets of Langerhans / cytology. Peptide Hormones / pharmacology
  • [MeSH-minor] Caspase 3 / metabolism. Cell Culture Techniques. Cell Division / drug effects. Cell Membrane / drug effects. Cell Membrane / physiology. Cyclic AMP / metabolism. Ghrelin / secretion. Glucagon-Like Peptide 1 / secretion. Humans. Insulin Receptor Substrate Proteins. Intracellular Signaling Peptides and Proteins / drug effects. Intracellular Signaling Peptides and Proteins / metabolism. Phosphoproteins / drug effects. Phosphoproteins / metabolism


84. Ringel J, Jesnowski R, Moniaux N, Lüttges J, Ringel J, Choudhury A, Batra SK, Klöppel G, Löhr M: Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res; 2006 Sep 15;66(18):9045-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma.
  • To understand the role of ADAM17/tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE) in pancreatic ductal adenocarcinoma (PDAC), we investigated its expression, function, and in vitro regulation.
  • ADAM17/TACE mRNA was expressed in 3 of 10 normal pancreatic tissues, 6 of 8 samples from patients with chronic pancreatitis, 10 of 10 PDAC tissues, and 9 of 9 pancreatic cancer cell lines, but it was absent in primary duct epithelial cells.
  • Immunohistochemical staining revealed positive cancer cells in 8 of 10 PDACs but no staining of ducts in normal pancreas.
  • ADAM17/TACE was found in 0 of 16 pancreatic intraepithelial neoplasia (PanIN)-1A lesions, 1 of 30 PanIN-1B lesions, 2 of 13 PanIN-2 lesions but, in 13 of 15 PanIN-3 lesions, associated with PDAC.
  • Western blot, flow cytometry, and confocal microscopy analyses showed the aberrant expression of ADAM17/TACE protein in pancreatic cancer cell lines.
  • The proteolytic activity of ADAM17/TACE, assessed by the release of TNF-alpha, was inhibited by TNF-alpha protease inhibitor.
  • Furthermore, ADAM17/TACE mRNA expression was down-regulated in pancreatic cancer cells arrested in G2-M phase as well as in a time-dependent manner after TNF-alpha and interleukin-6 incubation.
  • [MeSH-major] ADAM Proteins / biosynthesis. Carcinoma, Pancreatic Ductal / enzymology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / enzymology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Cell Cycle / genetics. Cell Growth Processes / genetics. Cell Line, Tumor. Disease Progression. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Immunohistochemistry. Neoplasm Invasiveness. Pancreatitis, Chronic / enzymology. Pancreatitis, Chronic / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982746.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA772712
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
  •  go-up   go-down


85. Hauge-Evans AC, Richardson CC, Milne HM, Christie MR, Persaud SJ, Jones PM: A role for kisspeptin in islet function. Diabetologia; 2006 Sep;49(9):2131-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A role for kisspeptin in islet function.
  • AIMS/HYPOTHESIS: We investigated the production of kisspeptin (KISS1) and the KISS1 receptor, GPR54, in pancreatic islets and determined the effects of exogenous kisspeptin on insulin secretion.
  • METHODS: RT-PCR and immunohistochemistry were used to detect expression of KISS1 and GPR54 mRNAs and the production of KISS1 and GPR54 in human and mouse islets and in beta (MIN6) and alpha- (alphaTC1) cell lines.
  • RESULTS: KISS1 and GPR54 mRNAs were both detected in human and mouse islets, and GPR54 mRNA expression was also found in the MIN6 and alphaTC1 endocrine cell lines.
  • In sections of mouse pancreas, KISS1 and GPR54 immunoreactivities were co-localised in both beta and alpha cells within islets, but were not detected in the exocrine pancreas.
  • In contrast, KISS1 inhibited insulin secretion from MIN6 cells at both 2 and 20 mmol/l glucose.
  • KISS1 had no significant effect on glucagon secretion from mouse islets.
  • CONCLUSIONS/INTERPRETATION: This is the first report to show that the GPR54/KISS1 system is expressed in the endocrine pancreas, where it influences beta cell secretory function.
  • These observations suggest an important role for this system in the normal regulation of islet function.
  • [MeSH-major] Islets of Langerhans / metabolism. Proteins / physiology. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Gene Expression. Glucagon / metabolism. Humans. Immunohistochemistry. In Vitro Techniques. Insulin / secretion. Kisspeptins. Mice. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / metabolism. Receptors, G-Protein-Coupled / physiology. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. GLUCAGON .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1761-6 [15665093.001]
  • [Cites] Mol Cell Endocrinol. 2002 Jun 14;191(2):167-76 [12062900.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34631-6 [11457843.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1319-28 [15020672.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 4;88(23):1731-7 [8944003.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3917-25 [15932928.001]
  • [Cites] Steroids. 2004 Aug;69(8-9):531-6 [15288765.001]
  • [Cites] J Histochem Cytochem. 2001 Jun;49(6):767-76 [11373323.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4565-74 [15242985.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):143-5 [14724452.001]
  • (PMID = 16826407.001).
  • [ISSN] 0012-186X
  • [Journal-full-title] Diabetologia
  • [ISO-abbreviation] Diabetologia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Insulin; 0 / KISS1 protein, human; 0 / KISS1R protein, human; 0 / Kiss1 protein, mouse; 0 / Kiss1r protein, mouse; 0 / Kisspeptins; 0 / Proteins; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Tumor Suppressor Proteins; 9007-92-5 / Glucagon
  •  go-up   go-down


86. Wang HW, Breslin MB, Lan MS: Pdx-1 modulates histone H4 acetylation and insulin gene expression in terminally differentiated alpha-TC-1 cells. Pancreas; 2007 Mar;34(2):248-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pdx-1 modulates histone H4 acetylation and insulin gene expression in terminally differentiated alpha-TC-1 cells.
  • OBJECTIVES: Islet-associated transcription factors play a critical role in regulating pancreatic endocrine cell differentiation and islet hormone gene expression.
  • Both alpha- and beta-cells differentiate from a common endocrine precursor cell.
  • Therefore, it is important to reveal the differential gene expression profiles between alpha- and beta-cells that can direct their terminal cell fates. alpha-TC-1 and beta-TC-1 are 2 terminally differentiated islet tumor cell lines derived from islets transformed by promoter-specific driven SV40 T antigen overexpression.
  • In this study, we demonstrated that Pdx-1 is a potent transcriptional regulator of endogenous insulin gene expression in alpha-TC-1 cells.
  • RESULTS: Differential transcription factor expression profiles of alpha-TC-1 and beta-TC-1 cells revealed that INSM-1 and Pdx-1 transcription factors were expressed exclusively in beta-TC-1 cells.
  • Overexpression of Ad-Pdx-1 in alpha-TC-1 cells induced insulin gene expression.
  • Chromatin immunoprecipitation assays in Ad-Pdx-1 alpha-TC-1 cells demonstrated Pdx-1 occupancy and the hyperacetylation of histone H4 in the insulin promoter region.
  • CONCLUSIONS: Collectively, these experiments revealed that Pdx-1 is a potent transcriptional regulator that is capable of modulating histone H4 acetylation and activates the insulin gene in a terminally differentiated glucagonoma cell line.
  • [MeSH-major] Glucagon-Secreting Cells / physiology. Histones / metabolism. Homeodomain Proteins / metabolism. Insulin / genetics. Insulin-Secreting Cells / physiology. Trans-Activators / metabolism
  • [MeSH-minor] Acetylation. Animals. Cell Differentiation. Cell Line, Tumor. Gene Expression / physiology. Mice. Mice, Transgenic. Pancreatic Neoplasms. Polymerase Chain Reaction. Promoter Regions, Genetic / physiology. Transcription Factors / genetics. Transcription, Genetic / physiology

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312465.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK061436
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 0 / Homeodomain Proteins; 0 / Insulin; 0 / Trans-Activators; 0 / Transcription Factors; 0 / pancreatic and duodenal homeobox 1 protein
  •  go-up   go-down


87. Masamune A, Satoh M, Kikuta K, Suzuki N, Satoh K, Shimosegawa T: Ellagic acid blocks activation of pancreatic stellate cells. Biochem Pharmacol; 2005 Sep 15;70(6):869-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ellagic acid blocks activation of pancreatic stellate cells.
  • Activated pancreatic stellate cells (PSCs) play a pivotal role in the pathogenesis of pancreatic fibrosis and inflammation.
  • We here evaluated the effects of ellagic acid on the activation and cell functions of PSCs.
  • PSCs were isolated from rat pancreas tissue and used in their culture-activated, myofibroblast-like phenotype unless otherwise stated.
  • Ellagic acid inhibited platelet-derived growth factor (PDGF)-BB-induced proliferation and migration, interleukin (IL)-1beta- and tumor necrosis factor (TNF)-alpha-induced monocyte chemoattractant protein-1 production, and expression of alpha-smooth muscle actin and collagen genes.
  • Ellagic acid inhibited IL-1beta- and TNF-alpha-induced activation of activator protein-1 and mitogen-activated protein kinases (extracellular signal-regulated kinase, c-Jun N-terminal kinase and p38 mitogen-activated protein kinase), but not of nuclear factor-kappaB.
  • In addition, ellagic acid inhibited transformation of freshly isolated cells to an activated, myofibroblast-like phenotype.
  • In conclusion, ellagic acid inhibited key cell functions and activation of PSCs.
  • [MeSH-major] Ellagic Acid / pharmacology. Pancreas / drug effects
  • [MeSH-minor] Animals. Base Sequence. Blotting, Western. Cell Movement / drug effects. Cell Proliferation / drug effects. Cells, Cultured. Chemokine CCL2 / metabolism. DNA Primers. Electrophoretic Mobility Shift Assay. Male. Phosphorylation. Platelet-Derived Growth Factor / antagonists & inhibitors. Platelet-Derived Growth Factor / physiology. Polymerase Chain Reaction. Proto-Oncogene Proteins c-sis. Rats. Rats, Wistar


88. Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, Giacomi N, O'Connor J, Méndez G, Roca E, Buenos Aires and La Plata Argentina Argentum Working Group: Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis; 2010 Mar;42(3):220-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The somatostatin receptors types 1-5 expression in a series including 100 gastro-entero-pancreatic endocrine tumours were analysed.
  • METHODS: From a prospectively built database of patients with gastro-entero-pancreatic endocrine tumours referred from three institutions, 100 cases with clinical and pathological data were selected.
  • Somatostatin receptors expression by immunohistochemistry with somatostatin receptor types 1-5 antibodies in tissue paraffin sections were studied and correlated with the histological diagnosis according to the WHO classification, location and functional status.
  • RESULTS: Of the 100 cases, 67 were gastrointestinal tumours, 25 pancreatic and 8 liver metastasis of unknown origin.
  • Thirty-one of them were functioning tumours: 2 insulinomas, 5 gastrinomas, 1 glucagonoma and 23 carcinoids.
  • Somatostatin receptors expression was less frequent in pancreatic than in gastrointestinal tumours.
  • CONCLUSIONS: Immunohistochemistry revealed that somatostatin receptors were highly expressed in both primary and metastatic gastro-entero-pancreatic endocrine tumours with heterogeneous staining distribution.
  • It proved to be a reliable technique even in small tumour samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • [CommentIn] Dig Liver Dis. 2010 Mar;42(3):173-4 [20117969.001]
  • (PMID = 19819769.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Somatostatin
  •  go-up   go-down


89. Lee LF, Xu B, Michie SA, Beilhack GF, Warganich T, Turley S, McDevitt HO: The role of TNF-alpha in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: analysis of dendritic cell maturation. Proc Natl Acad Sci U S A; 2005 Nov 1;102(44):15995-6000
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of TNF-alpha in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: analysis of dendritic cell maturation.
  • TNF-alpha has been linked to the development of type 1 diabetes (T1D).
  • We previously reported that neonatal treatment of nonobese diabetic (NOD) mice with TNF-alpha accelerated the onset of T1D, whereas TNF-alpha blockade in the same time period resulted in a complete absence of diabetes.
  • The mechanisms by which TNF-alpha modulates development of T1D in NOD mice remain unclear.
  • Here we tested the effects of TNF-alpha on the maturation of dendritic cells (DCs) in the NOD mouse.
  • We found that neonatal treatment with TNF-alpha caused an increase in expression of maturation markers on CD11c(+)CD11b(+) DC subpopulations, whereas treatment with anti-TNF-alpha resulted in a decrease in expression of maturation markers in the CD11c(+)CD11b(+) subset.
  • Moreover, neonatal treatment with TNF-alpha resulted in skewed development of a CD8alpha(+)CD11b(-)CD11c(+) DC subset such that TNF-alpha decreases the CD8alpha(+)CD11c(+) DC subset, increases the CD11c(+)CD11b(+) subset, and causes an increase in the expression of CD40 and CD54 on mature DCs capable of inducing immunity.
  • Anti-TNF-alpha-treated mice had an increase in the CD8alpha(+)CD11c(+) DCs.
  • Notably, adoptively transferred naïve CD4(+) T cells from BDC2.5 T cell receptor transgenic mice proliferated in the pancreatic lymph nodes in TNF-alpha-treated NOD mice but not in anti-TNF-alpha-treated mice.
  • Finally, we show that anti-TNF-alpha-treated mice showed immunological tolerance to islet cell proteins.
  • We conclude that TNF-alpha plays an important role in the initiation of T1D in the NOD mouse by regulating the maturation of DCs and, thus, the activation of islet-specific pancreatic lymph node T cells.

  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1987 Oct 15-21;329(6140):599-604 [3309680.001]
  • [Cites] Jikken Dobutsu. 1980 Jan;29(1):1-13 [6995140.001]
  • [Cites] Annu Rev Immunol. 1990;8:647-79 [2188676.001]
  • [Cites] Reg Immunol. 1992 Sep-Oct;4(5):263-73 [1290746.001]
  • [Cites] Cell. 1993 Sep 24;74(6):1089-100 [8402882.001]
  • [Cites] Nature. 1993 Nov 4;366(6450):72-5 [8232539.001]
  • [Cites] J Exp Med. 1994 Sep 1;180(3):995-1004 [8064245.001]
  • [Cites] J Exp Med. 1995 Feb 1;181(2):607-17 [7836916.001]
  • [Cites] Cell. 1996 May 3;85(3):291-7 [8616883.001]
  • [Cites] Cell. 1996 May 3;85(3):311-8 [8616887.001]
  • [Cites] Immunogenetics. 1997;46(1):29-34 [9148785.001]
  • [Cites] J Exp Med. 1997 May 5;185(9):1573-84 [9151895.001]
  • [Cites] J Immunol. 1997 Jul 15;159(2):565-73 [9218570.001]
  • [Cites] J Exp Med. 1999 Jan 18;189(2):331-9 [9892615.001]
  • [Cites] Science. 2000 Apr 21;288(5465):505-11 [10775108.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):769-79 [11560993.001]
  • [Cites] Nature. 2001 Dec 13;414(6865):792-8 [11742411.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12287-92 [12221281.001]
  • [Cites] J Immunol. 2003 May 1;170(9):4437-40 [12707318.001]
  • [Cites] J Exp Med. 2003 Nov 17;198(10):1527-37 [14623908.001]
  • [Cites] J Immunol. 1988 Mar 1;140(5):1511-8 [3126228.001]
  • (PMID = 16247001.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K01 DK064656; United States / NIDDK NIH HHS / DK / R01 DK051705; United States / NIDDK NIH HHS / DK / K01DK064656; United States / NIDDK NIH HHS / DK / R01DK51705
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC1276103
  •  go-up   go-down


90. Mizuno T, Hiraoka H, Yoshioka C, Takeda Y, Matsukane Y, Shimoyama N, Morimoto M, Hayashi T, Okuda M: Superficial necrolytic dermatitis associated with extrapancreatic glucagonoma in a dog. Vet Dermatol; 2009 Feb;20(1):72-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial necrolytic dermatitis associated with extrapancreatic glucagonoma in a dog.
  • Based on histopathological findings, blood examinations and necropsy findings, the condition was diagnosed as superficial necrolytic dermatitis associated with a glucagon-secreting extrapancreatic neuroendocrine tumour.
  • Gross necropsy revealed tumour invasion into the spleen, liver, adrenal glands and mesenteric lymph nodes.
  • Immunohistochemical analysis of the neoplastic cells revealed that the tumour was a glucagonoma, consistent with earlier findings of persistent glucagonaemia and hypoaminoacidaemia.
  • [MeSH-major] Dermatitis / veterinary. Dog Diseases / pathology. Glucagonoma / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152590.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Wei D, Li J, Shen M, Jia W, Chen N, Chen T, Su D, Tian H, Zheng S, Dai Y, Zhao A: Cellular production of n-3 PUFAs and reduction of n-6-to-n-3 ratios in the pancreatic beta-cells and islets enhance insulin secretion and confer protection against cytokine-induced cell death. Diabetes; 2010 Feb;59(2):471-8
PDF icon [Fulltext service] Download